study_arm,TrialID,url,Scientific_title,primary_purpose,multicentre,Study_design,control_arm,randomisation,blinding,prospective,Source_registry,phase_clean,region_Africa,region_N_America,region_L_America,region_Asia,region_Europe,region_Oceania,Date_enrollment_format,sample_size,Conditions,Bridging_flag,Day_inferred,Date_registration_format,Phase,Public_title,Countries,Primary_sponsor
im,ACTRN12617001086358,http://www.anzctr.org.au/ACTRN12617001086358.aspx,A prospective pilot study investigating the impact of obesity on seroprotection after influenza vaccination in children aged 11-17 years.,NA,NA,NULL,NA,NA,NA,Yes,ANZCTR,Phase 4,No,No,No,No,No,Yes,2018-04-02,50,Obesity in children and adolescents;Response to influenza vaccination,FALSE,FALSE,2017-07-26,Phase 4,A study on the influence of obesity on the protection after influenza vaccination in children aged 11-17 years.,Australia,Women's and Children's Hospital
im,ACTRN12618001090202,https://anzctr.org.au/ACTRN12618001090202.aspx,Coadministration of Malignancy and Infection specific T cells after allogeneic stem cell Transplant for Acute Leukaemia with CD34+ selected stem cells,Treatment,NA,Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety/efficacy;,No,Not applicable,No,Yes,ANZCTR,Phase 1,No,No,No,No,No,Yes,2018-10-12,20,Acute Leukaemia;Cytomegalovirus;Epstein-Barr Virus;Varicella Zoster Virus;BK Virus;Influenza virus;Aspergillus; <br>Acute Leukaemia <br>Cytomegalovirus <br>Epstein-Barr Virus <br>Varicella Zoster Virus <br>BK Virus <br>Influenza virus <br>Aspergillus;Cancer - Leukaemia - Acute leukaemia;Infection - Studies of infection and infectious agents,FALSE,FALSE,2018-06-29,Phase 1,Coadministration of Malignancy and Infection specific T cells after allogeneic stem cell Transplant for Acute Leukaemia with CD34+ selected stem cells,Australia,"Western Sydney Local Health District, Westmead Hospital"
main,ACTRN12619000423112,https://anzctr.org.au/ACTRN12619000423112.aspx,STimulating ß3 Adrenergic Receptors to improve change in exercise performance on a graded treadmill  in patients with Peripheral Arterial Disease.,Treatment,NA,Purpose: Treatment; Allocation: Randomised controlled trial;,Yes,Yes,NA,Yes,ANZCTR,Phase 2,No,No,No,No,No,Yes,2019-03-14,100,Peripheral Arterial Disease; <br>Peripheral Arterial Disease;Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system,FALSE,FALSE,2019-03-14,Phase 2,The STAR-PAD trial is testing a new treatment for Peripheral Arterial Disease (PAD).,Australia,North Sydney Local Health District
main,ACTRN12619000720112,https://anzctr.org.au/ACTRN12619000720112.aspx,Exploring the role of androgen receptor blockade in increasing the expression of prostate specific membrane antigen (PSMA) and enhancing 68Ga-PSMA-11-PET/CT imaging in patients with metastatic prostate cancer,Other,NA,Purpose: Diagnosis; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Efficacy;,No,Not applicable,No,Yes,ANZCTR,Undefined,No,No,No,No,No,Yes,2019-06-03,40,Prostate Cancer; <br>Prostate Cancer;Cancer - Prostate,FALSE,FALSE,2019-05-13,Not Applicable,Exploring the role of androgen receptor blockade in increasing the expression of prostate specific membrane antigen (PSMA) and enhancing 68Ga-PSMA-11-PET/CT imaging in patients with metastatic prostate cancer,Australia,GenesisCare
im,ACTRN12619000828123,https://anzctr.org.au/ACTRN12619000828123.aspx,Resuscitation in Paediatric Sepsis Using Early Inotropes– – A Randomized Controlled Trial to Assess Impact on Survival Free of Organ Dysfunction,Treatment,NA,Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Safety/efficacy;,Yes,Yes,No,Yes,ANZCTR,Phase 2,No,No,No,No,No,Yes,2019-07-21,80,Sepsis;Septic Shock; <br>Sepsis <br>Septic Shock;Infection - Studies of infection and infectious agents;Emergency medicine - Resuscitation,FALSE,FALSE,2019-06-07,Phase 2,Resuscitation in Paediatric Sepsis Using Early Inotropes (RESPOND-ED),Australia,University of Queensland
covid,ACTRN12620000731998,https://anzctr.org.au/ACTRN12620000731998.aspx,Safety and efficacy of a pharmacological strategy using Losartan in hospital patients with COVID-19,Treatment,NA,Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Safety/efficacy;,Yes,Yes,No,Yes,ANZCTR,Phase 1,No,No,No,No,No,Yes,2020-09-01,36,COVID-19; <br>COVID-19;Respiratory - Other respiratory disorders / diseases;Inflammatory and Immune System - Other inflammatory or immune system disorders;Infection - Other infectious diseases,FALSE,FALSE,2020-07-13,Phase 1,Will treating the overwhelming patient response with medications affect COVID-19 mortality?,Australia,NSW Health via the Hunter New England Local Health District
im,ChiCTR-IIR-16008507,http://www.chictr.org.cn/showproj.aspx?proj=14377,"A Randomized, Blind, active-controlled trials to evaluate the safety and immunogenicity of Quadrivalent influenza vaccine (Split Virion) for Human use in the healthy subjects among 6-months to 3 years old",NA,NA,Randomized parallel controlled trial,Yes,Yes,Yes,Yes,ChiCTR,Phase 3,No,No,No,Yes,No,No,2016-05-20,2070,Influenza,FALSE,FALSE,2016-05-20,III (Phase III study),"A Randomized, Blind, active-controlled trials to evaluate the safety and immunogenicity of Quadrivalent influenza vaccine (Split Virion) for Human use in the healthy subjects among 6-months to 3 years old",China,Hubei provincial center for disease control and prevention
im,ChiCTR-IPQ-16008781,http://www.chictr.org.cn/showproj.aspx?proj=14665,Effects of glucocorticoid on Changes of pulmonary function and serum cortisol during rheumatic valve replacemental perioperation,NA,NA,Quasi-randomized controlled,Yes,No,NA,Yes,ChiCTR,Phase 4,No,No,No,Yes,No,No,2016-10-01,180,Rheumatic heart valve disease; cardiac insufficiency; respiratory insufficiency,FALSE,FALSE,2016-07-04,Post-market,Effects of glucocorticoid on changes of pulmonary function and serum cortisol during rheumatic valve replacemental perioperation,China,Department of Cardiothoracic Surgery of the First Affiliated Hospital of Chongqing Medical University
im,ChiCTR1800014694,http://www.chictr.org.cn/showproj.aspx?proj=25120,Clinical observation on efficacy of ulinastatin and antibiotic treatment for severe pneumonia in ICU,Treatment,NA,Randomized parallel controlled trial,Yes,Yes,NA,No,ChiCTR,Undefined,No,No,No,Yes,No,No,2015-10-01,60,severe pneumonia,FALSE,FALSE,2018-01-30,Other,Clinical observation on efficacy of ulinastatin and antibiotic treatment for severe pneumonia in ICU,China,Wuxi Huishan District People's Hospital
main,ChiCTR1900022258,http://www.chictr.org.cn/showproj.aspx?proj=36344,Effects of coenzyme Q10 on endothelial and cardiac function in patients undergoing hemodialysis: a pilot randomized controlled trial,NA,NA,Parallel,Yes,Yes,NA,Yes,ChiCTR,Phase 1,No,No,No,Yes,No,No,2019-04-22,60,end-stage renal disease,FALSE,FALSE,2019-04-02,0,Effects of coenzyme Q10 on cardiovascular function in patients undergoing hemodialysis: a pilot randomized controlled trial,China,the 306th Hospital of Chinese PLA
main,ChiCTR1900022351,http://www.chictr.org.cn/showproj.aspx?proj=35137,"A prospective, multi-center, randomized controlled clinical trial for perioperative optimal bridge strategy on antithrombotic therapy of patients with a recently implanted coronary drug-eluting stent undergoing non-cardiac surgery",NA,Yes,Parallel,Yes,Yes,NA,Yes,ChiCTR,Phase 4,No,No,No,Yes,No,No,2019-05-01,1600,coronary artery disease,FALSE,FALSE,2019-04-07,4,"A prospective, multi-center, randomized controlled clinical trial for perioperative optimal bridge strategy on antithrombotic therapy of patients with a recently implanted coronary drug-eluting stent undergoing non-cardiac surgery",China,"Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine"
main,ChiCTR1900022488,http://www.chictr.org.cn/showproj.aspx?proj=37970,A randomized controlled study for puerarin regulates gut microbiota of patients with carotid atherosclerosis,NA,NA,Parallel,Yes,Yes,NA,Yes,ChiCTR,Phase 1,No,No,No,Yes,No,No,2019-05-01,20,Carotid atherosclerosis,FALSE,FALSE,2019-04-13,0,A randomized controlled study for puerarin regulates gut microbiota of patients with carotid atherosclerosis,China,"Zhujiang Hospital, Southern Medical University"
im,ChiCTR1900023507,http://www.chictr.org.cn/showproj.aspx?proj=31221,The study of ideal anesthetic regimen for drug-induced sleep endoscopy based on EEG monitoring in children with obstructive sleep apnea,NA,NA,Parallel,Yes,NA,NA,No,ChiCTR,Phase 1,No,No,No,Yes,No,No,2018-08-01,100,Obstructive Sleep Apnea,FALSE,FALSE,2019-05-31,0,The study of ideal anesthetic regimen for drug-induced sleep endoscopy based on EEG monitoring in children with obstructive sleep apnea,China,"Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai"
main,ChiCTR1900023825,http://www.chictr.org.cn/showproj.aspx?proj=39847,"Platelet inhibition in ACS patients after PCI by standard dose ticagrelor, low-dose ticagrelor and standard dual anti-platelet therapy after shortening the duration of dual anti-platelet therapy",NA,NA,Parallel,Yes,NA,NA,Yes,ChiCTR,Phase 4,No,No,No,Yes,No,No,2019-07-01,150,acute coronary syndrome,FALSE,FALSE,2019-06-13,4,Platelet inhibition in ACS patients after PCI by shortening the duration of dual antiretroviral therapy and low-dose ticagrelor,China,Tianjin Union Medical Center
im,ChiCTR1900024894,http://www.chictr.org.cn/showproj.aspx?proj=41373,Clinical study for moderate sedation with low dose propofol combined with sufentanil at BIS's direction in gastroscopy of patients with snoring,NA,NA,Parallel,Yes,NA,NA,Yes,ChiCTR,Phase 1,No,No,No,Yes,No,No,2019-08-03,136,Sleep apnea,FALSE,FALSE,2019-08-02,0,Clinical study for moderate sedation with low dose propofol combined with sufentanil at BIS's direction in gastroscopy of patients with snoring,China,"The Second Affiliated Hospital, Jiaxing College"
main,ChiCTR1900026242,http://www.chictr.org.cn/showproj.aspx?proj=43382,Study for the therapeutic effect of heparin in the treatment of Pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome,Treatment,NA,Parallel,Yes,NA,NA,Yes,ChiCTR,Phase 4,No,No,No,Yes,No,No,2019-10-01,60,hepatic sinusoidal obstruction syndrome,FALSE,FALSE,2019-09-28,4,Study for the effect of heparin in the treatment of Pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome,China,"Division of Gastroenterology, Union Hosptial, Tongji Medical College, Huazhong University of Science and Technology"
main,ChiCTR1900026494,http://www.chictr.org.cn/showproj.aspx?proj=44030,A randomized controlled tiral for the effect of preoperative Vitamin D supplementation on the incidence of Post Operative Cognitive Dysfunction in old patients after surgery,NA,NA,Parallel,Yes,Yes,NA,Yes,ChiCTR,Phase 1,No,No,No,Yes,No,No,2019-10-14,120,Postoperative cognitive dysfunction,FALSE,FALSE,2019-10-12,0,A randomized controlled tiral for the effect of preoperative Vitamin D supplementation on the incidence of Post Operative Cognitive Dysfunction in old patients after surgery,China,"Department of Anesthesiology, Peking University First Hospital"
main,ChiCTR1900027146,http://www.chictr.org.cn/showproj.aspx?proj=45130,China Children's Leukemia Group (CCLG) - AML2019 study on pediatric acute myeloid leukemia,NA,NA,Parallel,Yes,NA,NA,No,ChiCTR,Phase 4,No,No,No,Yes,No,No,2019-11-01,600,pediatic acute myeloid leukemia,FALSE,FALSE,2019-11-02,4,China Children's Leukemia Group (CCLG) - AML2019 study on pediatric acute myeloid leukemia,China,Capital Medical University Beijing Children's Hospital
main,ChiCTR1900027678,http://www.chictr.org.cn/showproj.aspx?proj=44407,GC012F injection (BCMA/CD19 CAR-T) in the treatment of recurrent refractory BCMA+ multiple myeloma,Treatment,NA,Single arm,No,Not applicable,NA,Yes,ChiCTR,Phase 1,No,No,No,Yes,No,No,2019-11-24,12,BCMA+Multiple Myeloma,FALSE,FALSE,2019-11-23,0,GC012F injection (BCMA/CD19 CAR-T) in the treatment of recurrent refractory BCMA+ multiple myeloma,China,The First Affiliated Hospital of Anhui Medical University
im,ChiCTR1900028497,http://www.chictr.org.cn/showproj.aspx?proj=42626,"A randomized, double-blind, placebo controlled trial for Chai-shi-Tui-Re (CHASE) granules for influenza A",NA,NA,Parallel,Yes,Yes,Yes,Yes,ChiCTR,Phase 4,No,No,No,Yes,No,No,2019-12-23,170,Influenza A,FALSE,FALSE,2019-12-23,4,Effectiveness of Chai-shi-Tui-Re (CHASE)  granules for influenza A: a randomized controlled trial,China,Guangdong Provincial Hospital of  Chinese Medicine
covid,ChiCTR2000029813,http://www.chictr.org.cn/showproj.aspx?proj=49425,Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19),Treatment,NA,Parallel,Yes,NA,NA,Yes,ChiCTR,Phase 1,No,No,No,Yes,No,No,2020-02-14,72,Novel Coronavirus Pneumonia (COVID-19),FALSE,FALSE,2020-02-14,0,Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19),China,Shanghai Public Health Clinical Center
covid,ChiCTR2000030033,http://www.chictr.org.cn/showproj.aspx?proj=49703,A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19),NA,NA,Parallel,Yes,NA,NA,Yes,ChiCTR,Undefined,No,No,No,Yes,No,No,2020-02-24,828,Novel Coronavirus Pneumonia (COVID-19),FALSE,FALSE,2020-02-21,New Treatment Measure Clinical Study,A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19),Chinese,The First Affiliated Hospital of Guangzhou Medical University
covid,ChiCTR2000030089,http://www.chictr.org.cn/showproj.aspx?proj=49889,"A randomized, open-label, controlled trial for the efficacy and safety of  Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)",Treatment,NA,Parallel,Yes,Yes,No,Yes,ChiCTR,Phase 4,No,No,No,Yes,No,No,2020-02-28,60,Novel Coronavirus Pneumonia(COVID-19),FALSE,FALSE,2020-02-22,4,A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19),China,Shanghai Changzheng Hospital
covid,ChiCTR2000030170,http://www.chictr.org.cn/showproj.aspx?proj=50017,Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19),Treatment,NA,Factorial,Yes,NA,NA,No,ChiCTR,Phase 1,No,No,No,Yes,No,No,2020-02-15,16,Novel Coronavirus Pneumonia (COVID-19),FALSE,FALSE,2020-02-24,0,Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19),China,Shanghai Public Health Clinical Center
covid,ChiCTR2000030469,http://www.chictr.org.cn/showproj.aspx?proj=50082,A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19),Treatment,NA,Parallel,Yes,Yes,NA,No,ChiCTR,Phase 1,No,No,No,Yes,No,No,2020-02-27,96,Novel Coronavirus Pneumonia (COVID-19),FALSE,FALSE,2020-03-02,0,A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19),China,Shanghai University of TCM
covid,ChiCTR2000030804,http://www.chictr.org.cn/showproj.aspx?proj=51018,Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial,NA,NA,Parallel,Yes,Yes,NA,No,ChiCTR,Phase 4,No,No,No,Yes,No,No,2020-02-01,128,Novel Coronavirus Pneumonia (COVID-19),FALSE,FALSE,2020-03-15,4,Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial,China,Maoming People's Hospital
covid,ChiCTR2000030944,http://www.chictr.org.cn/showproj.aspx?proj=50199,"An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia",NA,Yes,Parallel,Yes,NA,No,Yes,ChiCTR,Phase 1,No,No,No,Yes,No,No,2020-09-01,20,Novel Coronavirus Pneumonia (COVID-19),FALSE,FALSE,2020-03-18,1,Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19),China,The Second Affiliated Hospital of Nanchang University
covid,ChiCTR2000031453,http://www.chictr.org.cn/showproj.aspx?proj=51859,"Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial",Treatment,No,Parallel,Yes,Yes,NA,Yes,ChiCTR,Phase 4,No,No,No,Yes,No,No,2020-04-01,80,Novel Coronavirus Pneumonia (COVID-19),FALSE,FALSE,2020-04-01,4,"Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial",China,"Tongji Hospital of Tongji Medical College, Huazhong Science and Technology University"
covid,ChiCTR2000039000,http://www.chictr.org.cn/showproj.aspx?proj=62581,"Randomized, double-blinded, placebo parallel-controlled phase III clinical trial to evaluate the Immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in healthy population aged 18 years and above",NA,NA,Parallel,Yes,Yes,Yes,No,ChiCTR,Phase 3,Yes,No,No,No,No,No,2020-09-02,600,Novel coronavirus Pneumonia (COVID-19),FALSE,FALSE,2020-10-13,3,A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells),Morocco,China National Biotec Group Co.Ltd
im,CTRI/2017/09/009849,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=18803,Effectiveness of enteral ivabradine for heart rate control in septic shock â?? A randomized controlled trial.,NA,NA,"Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Open Label",Yes,Yes,No,Yes,CTRI,Undefined,No,No,No,Yes,No,No,2018-01-01,60,Health Condition 1: null- Septic shock,FALSE,FALSE,2017-09-19,N/A,Trial of ivabradine for controlling high heart rate control in septic shock.,India,All India Institute of Medical Sciences New Delhi
im,CTRI/2017/11/010688,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=11981,Effect of Sildenafil on mortality in term Neonates with hypoxemic respiratory failure due to persistent pulmonary hypertension - SIPHON,NA,NA,"Randomized, Parallel Group, Placebo Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Double Blind Double Dummy",Yes,Yes,Yes,No,CTRI,Undefined,No,No,No,Yes,No,No,2015-06-20,24,Health Condition 1: null- Hypoxic Respiratory failure due to Pulmonary hypertensionHealth Condition 2: I270- Primary pulmonary hypertension,FALSE,FALSE,2017-11-28,N/A,A study on effect of Sildenafil on mortality of hypoxic babies with persistent pulmonary hypertension,India,DrDeepti
main,CTRI/2019/01/017332,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30522,An open label single arm non-comparativeStudy to assess effectiveness and safety ofZolpidem Tartrate in patients of insomniaWith Diabetes Mellitus,NA,NA,Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label,No,Not applicable,No,Yes,CTRI,Phase 4,No,No,No,Yes,No,No,2019-02-01,50,Health Condition 1: G470- Insomnia,FALSE,FALSE,2019-01-31,Phase 4,A scientific study to check how much the drug Zolpidem tartrate is effective and safe in the patients of Insomnia (slip disorder) with Diabetes Mellitus,India,Dr Faraz Farishta
main,CTRI/2019/02/017505,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31033,Evaluation of efficacy of optimized natural killer cells as an adjunct to allogeneic stem cell transplantation in the treatment of refractory acute myeloid leukemia - ONKAML,Treatment,NA,Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable,No,Not applicable,No,Yes,CTRI,Phase 2,No,No,No,Yes,No,No,2019-02-11,21,Health Condition 1: C920- Acute myeloblastic leukemia,FALSE,FALSE,2019-02-06,Phase 2,Natural killer cell treament for Blood cancer,India,Department of Biotechnology India
main,CTRI/2019/02/017575,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31281,"A double blind randomized study on comparision of safety and efficacy of caudal,thoracic epidural and intravenous analgesia in paediatric cardiac surgery",NA,NA,"Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Permuted block randomization, variable  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant and Investigator Blinded",Yes,Yes,Yes,Yes,CTRI,Undefined,No,No,No,Yes,No,No,2019-02-12,90,"Health Condition 1: Q214- Aortopulmonary septal defectHealth Condition 2: Q211- Atrial septal defectHealth Condition 3: Q212- Atrioventricular septal defectHealth Condition 4: Q251- Coarctation of aortaHealth Condition 5: Q209- Congenital malformation of cardiacchambers and connections, unspecifiedHealth Condition 6: Q233- Congenital mitral insufficiencyHealth Condition 7: Q205- Discordant atrioventricular connectionHealth Condition 8: Q203- Discordant ventriculoarterial connectionHealth Condition 9: Q202- Double outlet left ventricleHealth Condition 10: Q201- Double outlet right ventricleHealth Condition 11: Q225- Ebsteins anomalyHealth Condition 12: Q234- Hypoplastic left heart syndromeHealth Condition 13: Q226- Hypoplastic right heart syndromeHealth Condition 14: Q263- Partial anomalous pulmonary venousconnectionHealth Condition 15: Q250- Patent ductus arteriosusHealth Condition 16: Q213- Tetralogy of FallotHealth Condition 17: Q262- Total anomalous pulmonary venous connectionHealth Condition 18: Q210- Ventricular septal defect",FALSE,FALSE,2019-02-11,N/A,Comparative study of various analgesic methods in Pediatric cardiac surgery,India,vrajesh kumar kodali
main,CTRI/2019/02/017661,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31293,A Comparative Clinical Study of Arka And Apamarga Pratisaraneeya Kshara In The Management of Arsha,NA,NA,"Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant and Outcome Assessor Blinded",Yes,Yes,Yes,Yes,CTRI,Phase 3,No,No,No,Yes,No,No,2019-03-01,40,Health Condition 1: K641- Second degree hemorrhoids,FALSE,FALSE,2019-02-14,Phase 2/ Phase 3,management of ano rectal piles with kshara,India,Department of Shalya Tantra
main,CTRI/2019/04/018410,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31674,EVALUATION OF DIFFERENT CONCENTRATION OF BHRINGRAJ TAILA ON PALITYA,NA,NA,"Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label",Yes,Yes,No,Yes,CTRI,Undefined,No,No,No,Yes,No,No,2019-04-12,30,Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere,FALSE,FALSE,2019-04-03,N/A,Effect of Bhringraj Tail In Premature Graying of Hair,India,Rishikul campus
main,CTRI/2019/04/018467,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32630,Effectiveness of Anti-neuropathic medicines(Gabapentin andAmitryptiline) in Rheumatoid Arthritis patients for pain relief. - NIL,NA,NA,"Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Random Number Table  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant Blinded",Yes,Yes,Yes,Yes,CTRI,Phase 4,No,No,No,Yes,No,No,2019-04-08,30,Health Condition 1: M05- Rheumatoid arthritis with rheumatoid factor,FALSE,FALSE,2019-04-08,Phase 4,Effects of Gabapentin and Amitryptiline for pain management in Rheumatoid Arthritis patients.,India,ESI Institute of Pain Management
main,CTRI/2019/04/018681,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30558,Randomised control study on association between timing of zoledronic acid infusion and hip fracture healing in patients more than 50 years of age,NA,NA,Cluster Randomized Trial<br>  Method of generating randomization sequence:Other  Method of allocation concealment:Other  Blinding and masking:Outcome Assessor Blinded,Yes,Yes,Yes,Yes,CTRI,Phase 4,No,No,No,Yes,No,No,2019-04-25,300,Health Condition 1: M810- Age-related osteoporosis without current pathological fracture,FALSE,FALSE,2019-04-22,Post Marketing Surveillance,Association between timing of zoledronic acid infusion    and hip fracture healing in elderly patients.,India,Dr Harsh Jalan
main,CTRI/2019/05/018959,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32290,"Phase 3, Randomized, Open-label, Controlled,Multiple-Dose, Efficacy, Safety,Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 days to lesser than 18 Years of age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis",NA,Yes,Other<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label,Yes,Yes,No,Yes,CTRI,Phase 3,No,Yes,Yes,Yes,Yes,No,2019-06-30,56,Health Condition 1: N258- Other disorders resulting from impaired renal tubular function,FALSE,FALSE,2019-05-06,Phase 3,A Phase 3 Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis,Argentina;India;Republic of Korea;Russian Federation;Singapore;Taiwan;Turkey;Ukraine;United States of America;Malaysia,Amgen Technology Pvt Ltd
im,CTRI/2019/05/019109,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33492,A Randomized controlled trial to evaluate the efficacy of topical pharyngeal anaesthesia using 5 vs 10 sprays of 10% lignocaine during flexible bronchoscopy,NA,NA,"Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded",Yes,Yes,Yes,Yes,CTRI,Undefined,No,No,No,Yes,No,No,2019-06-01,300,Health Condition 1: J851- Abscess of lung with pneumoniaHealth Condition 2: J168- Pneumonia due to other specified infectious organismsHealth Condition 3: J981- Pulmonary collapseHealth Condition 4: J99- Respiratory disorders in diseasesclassified elsewhereHealth Condition 5: J22- Unspecified acute lower respiratory infection,FALSE,FALSE,2019-05-14,N/A,Comfort during Bronchoscopy procedure,India,Department of Pulmonary Medicine and Sleep Disorders
im,CTRI/2019/07/020174,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=34335,"COMPARISON OF EFFICACY OF ORAL AMOXICILLIN VERSUS PARENTERAL CEPHALOSPORIN IN TREATMENT OF UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA A PROSPECTIVE SINGLE BLINDED PARALLEL DESIGN,RANDOMIZED CONTROL TRIAL IN A TERTIARY CARE HOSPITAL OF METROPOLITAN    CITY.",Treatment,NA,"Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Investigator Blinded",Yes,Yes,Yes,Yes,CTRI,Phase 3,No,No,No,Yes,No,No,2019-07-15,100,"Health Condition 1: J189- Pneumonia, unspecified organism",FALSE,FALSE,2019-07-15,Phase 2/ Phase 3,ORAL MEDICATION IS AS EFFECTIVE AS INJECTABLE  MEDICATION IN TREATMENT OF PNEUMONIA,India,DR SUSHANT S MANE
main,CTRI/2019/08/020943,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=27713,"A Phase 2, randomized, prospective, double-masked, vehicle controlled study to assess the efficacy and safety of NexagonÂ® (NEXAGON) applied topically in subjects with corneal persistent epithelial defects (PED) resulting from severe ocular chemical and/or thermal injuries. - EXPEDE",NA,Yes,Other<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Centralized  Blinding and masking:Double Blind Double Dummy,Yes,Yes,Yes,Yes,CTRI,Phase 2,No,Yes,No,Yes,No,No,2020-05-15,108,Health Condition 1: H160- Corneal ulcer,FALSE,FALSE,2019-08-28,Phase 2,To study the efficacy and safety of NexagonÂ® (NEXAGON) applied topically in subjects with corneal persistent epithelial defects (PED) resulting from severe ocular chemical and/or thermal injuries.,India;United States of America,OcuNexus Therapeutics Inc
covid,CTRI/2020/06/025650,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44412,A Prospective Cohort Interventional Study Assessing the Safety and Outcome of Unani Medicine as a Prophylaxis in Population at risk of COVID-19,Prevention,NA,"Other
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label",NA,NA,No,Yes,CTRI,Phase 2,No,No,No,Yes,No,No,2020-06-15,4000,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,FALSE,2020-06-05,Phase 2,To assess the safety and outcome of herbal medicine in prevention of COVID-19 infection among high risk population,India,Ministry of AYUSH Government of India
covid,CTRI/2020/06/025998,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44707,To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients: A Double-Blind Randomized Controlled Trial - RNB,NA,NA,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Case Record Numbers  Blinding and masking:Participant and Investigator Blinded",Yes,Yes,Yes,Yes,CTRI,Phase 3,No,No,No,Yes,No,No,2020-06-30,60,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,FALSE,2020-06-20,Phase 3,Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients,India,Uttar Pradesh University of Medical Sciences
covid,CTRI/2020/07/026471,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45318,"A prospective, non-randomized, single-arm interventional study to assess the safety and efficacy of Siddha Sasthric Medicines â?? Fixed Regimen in the prevention of COVID-19 disease progression of asymptomatic, and mild at Siddha COVID Care Centre, Chennai, 2020 (SSM-FiRe) - SSM-FiRe",Prevention,NA,"Single Arm Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable",No,Not applicable,No,Yes,CTRI,Phase 2,No,No,No,Yes,No,No,2020-07-20,60,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,FALSE,2020-07-10,Phase 2,A clinical trial to study the effect and safety of the Siddha medicines in patients with Corona Virus disease,India,The Directorate of Indian Medicine and Homoeopathy
covid,CTRI/2020/07/026514,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45580,"A Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment  Or Sodium-Copper-Chlorophyllin Plus Standard Treatment  Versus Standard Treatment  in Cancer patients with  SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19.",Treatment,NA,"Randomized, Parallel Group, Multiple Arm Trial
  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label",Yes,Yes,No,Yes,CTRI,Phase 2,No,No,No,Yes,No,No,2020-07-22,200,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,FALSE,2020-07-13,Phase 2,Randomized Controlled Trial Of Resveretrol-Copper OR Sodium-Copper-Chlorophyllin Versus Standard Treatment In Severe Covid-19 Cancer Patients.,India,Tata Memorial Centre
covid,CTRI/2020/07/026789,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45111,"A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC",NA,NA,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Participant and Investigator Blinded",Yes,Yes,Yes,Yes,CTRI,Phase 2,No,No,No,Yes,No,No,2020-07-31,50,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,FALSE,2020-07-25,Phase 2,A clinical study to see effect of  ArtemiC in patients with COVID-19,India,MGC Pharmaceuticals Ltd
covid,CTRI/2020/08/027038,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46197,"A Prospective ,randomized ,double blind,placebo controlled study to access effects of nano ozonized hydrogen peroxide nebulization on results of RTPCR for noval corona virus thus infectivity and clinical course among mild to moderate sick Covid 19 patients HOPE in Covid 19(Hydrogen Peroxide Inhalation).",NA,NA,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:On-site computer system  Blinding and masking:Participant and Investigator Blinded",Yes,Yes,Yes,Yes,CTRI,Phase 3,No,No,No,Yes,No,No,2020-08-20,100,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,FALSE,2020-08-07,Phase 3,Study  to assess effects of nano ozonised hydrogen peroxide nebulisation on results of RT-PCR for novel corona Virus thus infectivity and clinical course among mild to moderate sick COVID-19 Patients,India,SN medical College
covid,CTRI/2020/08/027503,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44980,Low Dose Aspirin in Moderate to Severe SARS- CoV-2 Infected Patients: A Pilot Randomized Controlled Trial,NA,NA,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Outcome Assessor Blinded",Yes,Yes,Yes,Yes,CTRI,Undefined,No,No,No,Yes,No,No,2021-06-15,60,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,FALSE,2020-08-31,N/A,Effect of blood thinning medicine in COVID-19 infection,India,Dr Souvik Maitra
covid,CTRI/2020/09/027904,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47392,Autologous whole blood injection as treatment for Covid-19 infection,Treatment,NA,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label",Yes,Yes,No,Yes,CTRI,Undefined,No,No,No,Yes,No,No,2020-10-02,60,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,FALSE,2020-09-18,N/A,Autologous whole blood injection as treatment for Covid-19 infection,India,Dr M Christopher
covid,CTRI/2020/09/028088,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47829,"Open Label Randomized trial of Colchicine, Aspirin and Montelukast for prevention of Adult Multisystem Inflammatory Syndrome in SARS-CoV-2 patients - CAM-Covid-19",Prevention,NA,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label",Yes,Yes,No,Yes,CTRI,Undefined,No,No,No,Yes,No,No,2020-10-31,34,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Health Condition 2: J128- Other viral pneumonia
",FALSE,FALSE,2020-09-28,N/A,"Open Label Randomized trial of Colchicine, Aspirin and Montelukast in Covid-19",India,Vivek Chauhan
covid,CTRI/2020/10/028635,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48783,Clinical evaluation of Virunil a standardized ayurvedic herbal compound as an adjuvant in management of COVID-19,Treatment,NA,"Randomized, Parallel Group, Active Controlled Trial
  Method of generating randomization sequence:Other  Method of allocation concealment:Alternation  Blinding and masking:Open Label",Yes,Yes,No,Yes,CTRI,Phase 3,No,No,No,Yes,No,No,2020-11-02,150,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Health Condition 2: J99- Respiratory disorders in diseasesclassified elsewhere
",FALSE,FALSE,2020-10-26,Phase 2/ Phase 3,use of VIRUNIL an Ayurvedic medicie as a supportive treatment in management of COVID-19.,India,NRI ACADEMY OF SCIENCES
im,EUCTR2006-005558-63-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005558-63,"A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nonadjuvanted inactivated subunit influenza vaccine, when administered to adults affected by chronic diseases",NA,No,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: noParallel group: noCross over: noOther: yesOther trial design description: observer-blindIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 2",Yes,Yes,Yes,NA,EUCTR,Unreported,No,No,No,No,Yes,No,2006-11-28,NA,Influenza <br>MedDRA version: 18.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02],NCT00519064,FALSE,2016-03-24,NULL,"A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nonadjuvanted inactivated subunit influenza vaccine, when administered to adults affected by chronic diseases",Italy,Novartis Vaccines and Diagnostics S.r.l.
im,EUCTR2015-003026-14-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003026-14,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA",NA,Yes,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: yesOther trial design description: IV to oral switch If controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: yesOther specify the comparator: Matching Placebo to Delafloxacin oral, Moxifloxacin oral, Moxifloxacin IV and Linezolid IVNumber of treatment arms in the trial: 2",Yes,Yes,Yes,Yes,EUCTR,Phase 3,Yes,Yes,Yes,Yes,Yes,No,2016-09-12,860,Community-Acquired Bacterial Pneumonia <br>MedDRA version: 20.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08],EUCTR2015-003026-14-HU,FALSE,2016-06-01,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA,Serbia;United States;Slovenia;Greece;Spain;Ukraine;Russian Federation;Colombia;Hungary;Argentina;Poland;Brazil;Romania;South Africa;Bulgaria;Georgia;Latvia;Germany,"Melinta Therapeutics, Inc."
im,EUCTR2015-003119-39-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003119-39,effects of a short therpay of zolpidem with support servo-ventilation versus placebo in patients with central sleep apnea with chronic heart failure - ZODIAC,NA,NA,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 2",Yes,Yes,Yes,No,EUCTR,Phase 4,No,No,No,No,Yes,No,2015-10-29,NA,"chronic heart failure and central sleep apnea <br>MedDRA version: 18.1Level: PTClassification code 10040979Term: Sleep apnoea syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders <br>MedDRA version: 18.1Level: LLTClassification code 10019276Term: Heart disease, unspecifiedSystem Organ Class: 100000004849;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]",FALSE,FALSE,2016-02-25,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,effects of a short therpay of zolpidem with support servo-ventilation versus placebo in patients with central sleep apnea with chronic heart failure,France,Centre Hospitalier Universitaire de Grenoble
im,EUCTR2015-004546-26-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004546-26,"A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects with Uncomplicated Influenza A Infection",NA,Yes,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 3",Yes,Yes,Yes,Yes,EUCTR,Phase 2,Yes,Yes,No,No,Yes,No,2017-01-11,150,Influenza A infection <br>MedDRA version: 19.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02],EUCTR2015-004546-26-LV,FALSE,2016-12-01,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,"Clinical trial to see if there are differences in flu symptoms when people receive a single infusion of VIS410, the study medicine, compared with those who receive placebo and to find out if VIS410 is safe and well tolerated",Serbia;United States;Estonia;Ukraine;Lithuania;South Africa;Bulgaria;Latvia,"Visterra, Inc."
im,EUCTR2015-005383-42-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005383-42,"Use of buspiron in chemioreflex modulation and central apnea treatment in heart failure patients (BREATH: BuspiRon for chEmoreflex modulation and central Apnea treatment in Heart failure patients). Phase II, monocentric, cross-over, duble dummy, randomized and controlled, pilot study. - BREATH",Treatment,NA,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: yesOther: yesOther trial design description: pilot studyIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 2",Yes,Yes,Yes,No,EUCTR,Phase 2,No,No,No,No,Yes,No,2016-05-19,10,patient with central apneas syndrome and heart failure <br>MedDRA version: 20.0Level: LLTClassification code 10011949Term: Decompensation cardiacSystem Organ Class: 100000004849 <br>MedDRA version: 20.0Level: HLTClassification code 10040978Term: Sleep apnoeasSystem Organ Class: 100000004852;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14],FALSE,FALSE,2019-01-07,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,BuspiRon for chEmoreflex modulation and central Apnea treatment in Heart failure patients,Italy,FONDAZIONE TOSCANA GABRIELE MONASTERIO
im,EUCTR2015-005482-23-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005482-23,"Randomized, Double-Blind and Active-Controlled Study in Children and Adolescents Aged 3–17 Years to Assess the Safety and Immunogenicity of Abbott’s Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority versus Trivalent Influenza Vaccine.",NA,Yes,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 3",Yes,Yes,Yes,Yes,EUCTR,Phase 3,No,No,No,No,Yes,No,2016-07-28,1200,Prophylaxis of Influenza <br>MedDRA version: 20.0Level: HLTClassification code 10022005Term: Influenza viral infectionsSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02],EUCTR2015-005482-23-HU,FALSE,2016-04-25,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A blinded study to compare the safety and immune response in children and adolescents aged 3-17 years between Abbott's Candidate Quadrivalant Influenza and Trivalent Influenza Vaccine.,Hungary;Estonia;Finland;Poland;Lithuania;Germany,Abbott Biologicals B.V.
im,EUCTR2016-001557-41-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001557-41,"A Phase III, Multi-center, Single-dose, Randomized, Double-blind, Non-inferiority and Lot-to-lot Consistency Study of Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Influenza Vaccine (QIS) versus Fluarix Tetra Vaccine in Healthy Subjects.",NA,Yes,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 4",Yes,Yes,Yes,Yes,EUCTR,Phase 3,No,No,No,Yes,Yes,No,2016-09-09,2100,healthy volunteers <br>MedDRA version: 19.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02],FALSE,FALSE,2016-08-09,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,Immunogenicity and Safety Evaluation of AdimFlu-S (QIS) in Healthy Subjects.,Taiwan;Belgium,Adimmune Corporation
im,EUCTR2016-003433-20-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003433-20,Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute Myocarditis - ARAMIS,Treatment,NA,"Controlled: no                Randomised: yes                Open: no                Single blind: no                Double blind: yes                Parallel group: yes                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: no                Placebo: yes                Other: no                Number of treatment arms in the trial: 2",Yes,Yes,Yes,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2016-12-16,120,Patients hospitalized for Acute myocarditis <br>                MedDRA version: 19.0                Level: LLT                Classification code 10000932                Term: Acute myocarditis                System Organ Class: 100000004849            ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14],FALSE,FALSE,2016-11-04,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute MyocarditIS,France,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
im,EUCTR2016-004133-25-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004133-25,"A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) with a US-Licensed 2015-2016 Quadrivalent Inactivated Comparator Influenza Vaccine (Comparator QIV) in a Pediatric Population Aged 5 Through 17 Years of Age.",NA,Yes,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 2",Yes,Yes,Yes,NA,EUCTR,Phase 3,No,Yes,No,No,No,No,NA,2222,Prophylaxis for influenza virus infection <br>MedDRA version: 19.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02],NCT02545543,FALSE,2016-12-15,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A study to evaluate the immunogenicity and safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a pediatric population aged 5 through to 17 years of age,United States,Seqirus GmbH
im,EUCTR2016-004763-40-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004763-40,Immunogenicity and Safety of Quadrivalent Influenza Vaccine (VaxigripTetra™) in Pregnant Women,NA,NA,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: yes<br>Other trial design description: blind observer<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,NA,Yes,EUCTR,Phase 4,No,No,No,No,Yes,No,2017-04-05,729,Prophylaxix of influenza in Pregnant Women;Therapeutic area: Diseases [C] - Virus Diseases [C02],FALSE,FALSE,2017-03-16,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,Immunogenicity and Safety of Quadrivalent Influenza Vaccine (VaxigripTetra™) inPregnant Women,Finland,Sanofi Pasteur
im,EUCTR2017-001239-38-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001239-38,"A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of Age",NA,Yes,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: yes<br>Other trial design description: Observer blind<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,Yes,Yes,EUCTR,Phase 3,No,Yes,No,Yes,Yes,No,2017-10-23,10000,Seasonal influenza <br>MedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02],EUCTR2017-001239-38-FI,FALSE,2017-05-29,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,"A Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of Age",United States;Philippines;Canada;Finland;Thailand;Germany;United Kingdom,Medicago R&D Inc.
im,EUCTR2017-001270-41-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001270-41,"Norepinephrine alone vs Norepinephrine and Dobutamine in cardiogenic shock : a randomised, opened, cross-over study. Heart SHOCK-NORDOB Study - HEARTSCHOCK-NORDOB",NA,NA,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: yes<br>                Single blind: no<br>                Double blind: no<br>                Parallel group: no<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: yes<br>                Placebo: no<br>                Other: no<br>                Number of treatment arms in the trial: 2<br>",Yes,Yes,No,Yes,EUCTR,Phase 3,No,No,No,No,Yes,No,2019-07-17,42,Cardiogenic Shock;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14],NCT03340779,FALSE,2017-06-30,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): yes                Therapeutic use (Phase IV): no,"Norepinephrine alone vs Norepinephrine and Dobutamine in cardiogenic shock : a randomised, opened, cross-over study. Heart SHOCK-NORDOB Study",France,CHRU NANCY
main,EUCTR2017-002491-10-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002491-10,Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula,NA,Yes,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 1<br>",No,Not applicable,No,Yes,EUCTR,Phase 4,No,No,No,No,Yes,No,2020-03-10,50,Perianal fistulising Crohn´s disease <br>MedDRA version: 20.0Level: PTClassification code 10002156Term: Anal fistulaSystem Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06],NCT04118088,FALSE,2019-11-27,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,Postauthorization Safety Study of Darvadstrocel Repeat Administration,France;Czech Republic;Spain;Austria;Germany;United Kingdom,"Millennium Pharmaceuticals, Inc (MPI)"
im,EUCTR2017-003037-28-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003037-28,Efficacy of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease modifying anti-rheumatic drugs. - TOPIRA,NA,NA,"Controlled: yes                Randomised: yes                Open: yes                Single blind: no                Double blind: no                Parallel group: no                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: yes                Placebo: no                Other: no                Number of treatment arms in the trial: 2",Yes,Yes,No,Yes,EUCTR,Phase 4,No,No,No,No,Yes,No,2019-10-02,120,RA patients with active RA despite treatment with csDMARDs and previous use of max 1 TNFi. <br>                MedDRA version: 20.0                Level: PT                Classification code 10039073                Term: Rheumatoid arthritis                System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders            ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05],FALSE,FALSE,2019-07-22,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): yes,Efficacy of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease modifying anti-rheumatic drugs.,Netherlands,University Medical Center Utrecht
im,EUCTR2018-000005-23-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000005-23,Ghrelin treatment of comatose patients after cardiac arrest:                 A clinical trial to promote cerebral recovery - Ghrelin in coma,Treatment,NA,"Controlled: yes                Randomised: yes                Open: no                Single blind: no                Double blind: yes                Parallel group: no                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: no                Placebo: yes                Other: no                Number of treatment arms in the trial: 2",Yes,Yes,Yes,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2018-12-12,208,Brain damage after cardiac arrest;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],FALSE,FALSE,2018-11-19,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,Ghrelin treatment of comatose patients after cardiac arrest:                 A clinical trial to promote cerebral recovery,Netherlands,University of Twente
main,EUCTR2018-001271-20-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001271-20,"A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO",NA,Yes,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: no<br>                Single blind: no<br>                Double blind: yes<br>                Parallel group: yes<br>                Cross over: no<br>                Other: yes<br>                Other trial design description: partially blinded extension period<br>                If controlled, specify comparator, Other Medicinial Product: yes<br>                Placebo: yes<br>                Other: no<br>                Number of treatment arms in the trial: 12<br>",Yes,Yes,Yes,Yes,EUCTR,Phase 2,No,Yes,No,Yes,Yes,Yes,2019-06-13,660,Vitiligo <br>                MedDRA version: 20.0                Level: PT                Classification code 10047642                Term: Vitiligo                System Organ Class: 10040785 - Skin and subcutaneous tissue disorders            ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17],NCT03715829,FALSE,2019-04-30,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,A medical research study to evaluate the safety and effectiveness of two investigational medications for vitiligo,"United States;Taiwan;Canada;Belgium;Spain;Australia;Germany;Japan;Italy;Korea, Republic of","Pfizer Inc 235 East 42nd Street, New York, NY10017 US"
main,EUCTR2018-002152-32-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002152-32,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TENAYA) - TENAYA",NA,Yes,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: no<br>                Single blind: no<br>                Double blind: yes<br>                Parallel group: yes<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: yes<br>                Placebo: no<br>                Other: no<br>                Number of treatment arms in the trial: 2<br>",Yes,Yes,Yes,Yes,EUCTR,Phase 3,No,Yes,Yes,Yes,Yes,No,2019-04-04,640,Neovascular age-related macular degeneration <br>                MedDRA version: 20.0                Level: PT                Classification code 10071129                Term: Neovascular age-related macular degeneration                System Organ Class: 10015919 - Eye disorders            ;Therapeutic area: Diseases [C] - Eye Diseases [C11],NCT03823287,FALSE,2019-03-25,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): yes                Therapeutic use (Phase IV): no,A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (Tenaya),United States;Spain;Turkey;Russian Federation;Israel;Switzerland;United Kingdom;Italy;Hungary;Mexico;Canada;Poland;Brazil;Netherlands;Germany;Japan,F.Hoffmann La-Roche Ltd
main,EUCTR2018-002303-33-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002303-33,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy",Treatment,Yes,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 4",Yes,Yes,Yes,NA,EUCTR,Phase 3,No,Yes,Yes,Yes,Yes,No,2019-04-24,555,Focal-Onset Seizures <br>MedDRA version: 20.0Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],NCT03739840,FALSE,2019-05-21,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A study to test the efficacy and safety of padsevonil as treatment of focal-onset seizures in adult subjects with drug-resistant epilepsy,Serbia;United States;Portugal;Estonia;Slovakia;Greece;Spain;Italy;Switzerland;France;Denmark;Netherlands;Bosnia and Herzegovina;Finland;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Belgium;Poland;Croatia;Bulgaria;Germany;Sweden,UCB Biopharma SPRL
im,EUCTR2018-002470-42-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002470-42,Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study - FluSHED-2,NA,NA,"Controlled: no<br>Randomised: no<br>Open: no<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>",No,Not applicable,NA,Yes,EUCTR,Phase 4,No,No,No,No,Yes,No,2018-08-30,30,Prevention of influenza infection through immunisation <br>MedDRA version: 20.0Level: LLTClassification code 10016794Term: Flu vaccinationSystem Organ Class: 100000004865;Therapeutic area: Body processes [G] - Immune system processes [G12],NCT03735147,FALSE,2018-07-10,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,"An observational study of the nasal influenza vaccine, by measuring how much and what strains of flu virus are seen in the noses of children given the nasal flu vaccine in 2018-19, and comparing this to antibody levels in blood and oral fluid.",United Kingdom,Imperial College London JRC Office
im,EUCTR2018-002876-41-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002876-41,Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration) - PROLISA,NA,NA,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: no<br>                Single blind: no<br>                Double blind: yes<br>                Parallel group: yes<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: yes<br>                Other: no<br>                Number of treatment arms in the trial: 2<br>",Yes,Yes,Yes,No,EUCTR,Phase 3,No,No,No,No,Yes,No,NA,542,"Respiratory Distress Syndrome of preterm babies born < 32 weeks of gestational age;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]",FALSE,FALSE,2018-08-08,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): yes                Therapeutic use (Phase IV): no,Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration),France,CHU Grenoble-Alpes
im,EUCTR2018-003117-18-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003117-18,"A phase III randomized, controlled, open label multicenter clinical trial, with two parallel groups, to evaluate the efficacy of albumin administration in patients hospitalized with community-acquired pneumonia (ALBUCAP)",NA,Yes,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: STANDARD OF CARE<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,No,Yes,EUCTR,Phase 3,No,No,No,No,Yes,No,2019-07-10,360,Community-acquired pneumonia (CAP) <br>MedDRA version: 20.0Level: PTClassification code 10035664Term: PneumoniaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08],NCT04071041,FALSE,2019-04-12,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,To evaluate the efficacy of albumin administration in patients hospitalized with community-acquired pneumonia (ALBUCAP),Spain,Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge
main,EUCTR2018-003739-32-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003739-32,"Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ß) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors. - Actuate 1801: Phase 1/2 of 9-ING-41 in Refractory Malignancies",NA,Yes,"Controlled: noRandomised: noOpen: yesSingle blind: noDouble blind: noParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: noOther: no",No,Not applicable,No,Yes,EUCTR,Phase 2,No,Yes,No,No,Yes,No,2020-02-28,350,"Refractory Hematologic Malignancies or Solid Tumors <br>MedDRA version: 21.1Level: PTClassification code 10066476Term: Haematological malignancySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) <br>MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]",FALSE,FALSE,2019-10-30,Human pharmacology (Phase I): yesTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,"A clinical trial of a new drug known as 9-ING-41, that will take place inpatients with tumors or cancers that affect the blood and lymph system.9-ING-41 will be assessed as a standalone drug as well as being assessedwhen taken with chemotherapy drugs",France;United States;Spain;Denmark;Germany;Netherlands;United Kingdom,Actuate Therapeutics Inc
main,EUCTR2018-004024-11-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004024-11,"An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects",NA,Yes,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: yes<br>Other trial design description: Dose Escalation <br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 3<br>",No,Not applicable,No,Yes,EUCTR,Phase 2,No,No,No,Yes,Yes,No,2020-02-26,21,"Hemophilia B is a X-linked recessive bleeding disorder caused by mutations in the gene encoding clotting factor IX (FIX) that result in disruption of the normal clotting pathway. Hemophilia B affects 1 in 25,000 male births. Disease severity correlates directly with the concentration of functional FIX protein in the plasma. Severe disease is characterized as having <1% of normal plasma levels of FIX (100% = 1 IU activity/mL or approximately 5000 ng protein/mL). <br>MedDRA version: 20.0Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]",EUCTR2018-004024-11-ES,FALSE,2019-10-08,Human pharmacology (Phase I): yesTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,"A Phase 1/2 study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects",France;Hungary;Spain;Turkey;Austria;Germany;Italy,Baxalta Innovations GmbH
im,EUCTR2018-004056-37-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004056-37,"A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIRMARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY PATIENTS TOHOUSEHOLD CONTACTS - Centerstone",NA,Yes,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 2",Yes,Yes,Yes,Yes,EUCTR,Phase 3,Yes,Yes,Yes,Yes,Yes,No,2019-09-11,1130,Influenza <br>MedDRA version: 20.0Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 100000004862 <br>MedDRA version: 20.1Level: LLTClassification code 10022003Term: Influenza B virus infectionSystem Organ Class: 100000004862 <br>MedDRA version: 20.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862 <br>MedDRA version: 20.0Level: LLTClassification code 10016790Term: FluSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02],NCT03969212,FALSE,2019-07-24,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza from Otherwise Healthy Patients to Household Contacts,United States;Hong Kong;Greece;Spain;Costa Rica;Turkey;Israel;United Kingdom;Switzerland;India;Mexico;Argentina;Brazil;Singapore;South Africa;Japan;China,F. Hoffmann-La Roche Ltd
main,EUCTR2018-004451-20-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004451-20,"A  multicenter,  open  label,  single-arm  pilot  study  to  evaluate  the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)",NA,Yes,"<br>                Controlled: no<br>                Randomised: no<br>                Open: yes<br>                Single blind: no<br>                Double blind: no<br>                Parallel group: no<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: no<br>                Other: no<br>                Number of treatment arms in the trial: 1<br>",No,Not applicable,No,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2019-07-17,50,Adult men and women with palmoplantar pustulosis <br>                MedDRA version: 21.1                Level: PT                Classification code 10050185                Term: Palmoplantar pustulosis                System Organ Class: 10040785 - Skin and subcutaneous tissue disorders            ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17],FALSE,FALSE,2019-04-09,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,"A  multicenter,  open  label,  single-arm  pilot  study  to  evaluate  the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)",Germany,Rheinische Friedrich-Wilhelms-Universität Bonn
main,EUCTR2018-004567-31-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004567-31,"A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk",NA,Yes,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,Yes,Yes,EUCTR,Phase 3,No,Yes,Yes,Yes,Yes,Yes,2019-12-11,676,Metastatic Renal Cell Carcinoma <br>MedDRA version: 21.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04],EUCTR2018-004567-31-ES,FALSE,2019-05-20,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,"This is a randomized, double-blind, controlled trial to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated subjects with intermediate- and poor-risk advanced or metastatic RCC",United States;Hong Kong;Finland;Spain;Austria;Israel;Chile;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Netherlands;Germany;New Zealand,"Exelixis, Inc."
main,EUCTR2019-000069-19-PT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000069-19,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials - CLASSIC-MS,Treatment,Yes,"Controlled: noRandomised: noOpen: noSingle blind: noDouble blind: noParallel group: noCross over: noOther: yesOther trial design description: Ambispective; data from patients participating to past trials. No IMP treatment during this studyIf controlled, specify comparator, Other Medicinial Product: noPlacebo: noOther: no",No,Not applicable,NA,Yes,EUCTR,Phase 4,Yes,Yes,No,Yes,Yes,Yes,2019-10-14,1000,Multiple Sclerosis <br>MedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disorders <br>MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],EUCTR2019-000069-19-CZ,FALSE,2019-05-13,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials,"Romania;Serbia;United States;Portugal;Estonia;Morocco;Greece;Spain;Ukraine;Lebanon;Russian Federation;Switzerland;Italy;France;Australia;Tunisia;Latvia;Korea, Republic of;Finland;Lithuania;Austria;United Kingdom;Czech Republic;Canada;Poland;Belgium;Croatia;Bulgaria;Georgia;Norway;Germany;Sweden",Merck KGaA
main,EUCTR2019-000119-10-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000119-10,"An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis - JUVE-BRIGHT",NA,Yes,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,No,Yes,EUCTR,Phase 3,No,No,No,No,Yes,No,2019-08-06,42,Juvenile Idiopathic Arthritis Associated Uveitis or Anterior Antinuclear Antibody-Positive Uveitis <br>MedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11],EUCTR2019-000119-10-FR,FALSE,2019-04-17,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A study of Baricitinib in children and young adults with JIA associated eye inflammation,France;Germany;United Kingdom,Eli Lilly and Company
main,EUCTR2019-000733-39-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000733-39,"A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate to severe Ulcerative Colitis.",NA,Yes,"Controlled: noRandomised: noOpen: yesSingle blind: noDouble blind: noParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: noOther: noNumber of treatment arms in the trial: 1",No,Not applicable,No,Yes,EUCTR,Phase 2,No,Yes,No,No,Yes,No,2019-11-09,232,Moderate to Severe Ulcerative Colitis <br>MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06],EUCTR2019-000733-39-ES,FALSE,2019-09-12,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,Open-label maintenance therapy in moderate to severe Ulcerative Colitis patients,Serbia;Belarus;Slovakia;Slovenia;Spain;Ukraine;Ireland;Austria;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Netherlands;Germany,ABIVAX
main,EUCTR2019-001085-15-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001085-15,"Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections. - HEARTH-OF Study.",NA,NA,"Controlled: yes                Randomised: yes                Open: no                Single blind: no                Double blind: yes                Parallel group: yes                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: no                Placebo: yes                Other: no                Number of treatment arms in the trial: 2",Yes,Yes,Yes,Yes,EUCTR,Phase 4,No,No,No,No,Yes,No,2019-11-06,100,Patients presenting recurrent orofacial herpes infections (6 or more episodes within the 12-months’ period prior to their study entry). <br>                MedDRA version: 20.0                Level: HLT                Classification code 10019972                Term: Herpes viral infections                System Organ Class: 10021881 - Infections and infestations             <br>                MedDRA version: 20.1                Level: PT                Classification code 10067152                Term: Oral herpes                System Organ Class: 10021881 - Infections and infestations             <br>                MedDRA version: 21.1                Level: PT                Classification code 10019948                Term: Herpes simplex                System Organ Class: 10021881 - Infections and infestations            ;Therapeutic area: Diseases [C] - Virus Diseases [C02],FALSE,FALSE,2019-08-22,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): yes,"Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.",Belgium,LABO’LIFE Belgium sprl
main,EUCTR2019-001100-38-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001100-38,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study)",NA,Yes,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,Yes,Yes,EUCTR,Phase 3,No,Yes,No,No,Yes,No,2019-12-13,252,Multiple System Atrophy <br>MedDRA version: 21.1Level: PTClassification code 10064060Term: Multiple system atrophySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],NCT03952806,FALSE,2019-10-03,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study),United States;France;Austria;Germany;Italy;United Kingdom,"Biohaven Pharmaceuticals, Inc"
main,EUCTR2019-001222-98-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001222-98,"A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) - CheckMate73L",NA,Yes,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 3<br>",Yes,Yes,No,Yes,EUCTR,Phase 3,No,Yes,Yes,Yes,Yes,Yes,2019-08-28,1400,"Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) <br>MedDRA version: 20.0Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]",EUCTR2019-001222-98-SE,FALSE,2019-07-22,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery,"United States;Taiwan;Spain;Ireland;Russian Federation;Chile;Italy;Switzerland;United Kingdom;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Australia;Netherlands;Germany;Japan;China;Korea, Republic of;Sweden",Bristol-Myers Squibb International Corporation
main,EUCTR2019-001458-24-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001458-24,"APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) - A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy",NA,Yes,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 1",Yes,Yes,Yes,Yes,EUCTR,Phase 3,No,Yes,Yes,Yes,Yes,Yes,2019-11-12,300,Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) <br>MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14],NCT03997383,FALSE,2019-08-30,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy,"United States;Portugal;Hong Kong;Taiwan;Colombia;United Kingdom;Mexico;Argentina;Brazil;Australia;Denmark;Bulgaria;Japan;Korea, Republic of","Alnylam Pharmaceuticals, Inc."
main,EUCTR2019-001560-30-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001560-30,"Multicenter, single-blind, adaptive dose finding study of single intravenous injections of BAY 1747846 with corresponding blinded read in adult participants with known or highly suspected CNS lesions referred for contrast-enhanced MRI of the CNS",NA,Yes,"Controlled: yes<br>Randomised: no<br>Open: no<br>Single blind: yes<br>Double blind: no<br>Parallel group: no<br>Cross over: yes<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 1<br>",Yes,No,Yes,Yes,EUCTR,Phase 2,No,Yes,No,Yes,Yes,No,2020-05-04,180,"Central nervous system (CNS) pathology <br>MedDRA version: 22.1Level: LLTClassification code 10029820Term: Nuclear magnetic resonance imaging gadolinium-enhancedSystem Organ Class: 100000004848 <br>MedDRA version: 20.0Level: PTClassification code 10051290Term: Central nervous system lesionSystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]",NCT04307186,FALSE,2019-11-27,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,Study to find the appropriate dose of a new gadolinium-based contrast agent (GBCA) for adults undergoing magnetic resonance imaging (MRI) for known or highly suspected brain and/or spinal cord conditions,United States;Germany;Japan,Bayer AG
main,EUCTR2019-001565-33-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001565-33,"A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE-XT",NA,Yes,"Controlled: noRandomised: noOpen: noSingle blind: noDouble blind: noParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: noOther: noNumber of treatment arms in the trial: 1",No,Not applicable,No,No,EUCTR,Phase 3,No,Yes,No,Yes,Yes,No,2019-10-30,200,Generalized Myasthenia Gravis <br>MedDRA version: 20.0Level: LLTClassification code 10028415Term: MyastheniaSystem Organ Class: 100000004859;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],FALSE,FALSE,2019-11-01,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis,France;United States;Canada;Spain;Norway;Germany;Japan;Italy;United Kingdom,"Ra Pharmaceuticals, Inc."
main,EUCTR2019-001854-24-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001854-24,Long-term outcomes in immunologically low-risk kidney transplant recipients using tacrolimus.                Extension study of: Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study. - TACmono long-term.,NA,NA,"<br>                Controlled: no<br>                Randomised: no<br>                Open: no<br>                Single blind: no<br>                Double blind: no<br>                Parallel group: no<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: no<br>                Other: no<br>",No,Not applicable,NA,Yes,EUCTR,Phase 4,No,No,No,No,Yes,No,2019-08-07,76,kidney transplantation                vaccination responses;Therapeutic area: Body processes [G] - Immune system processes [G12],FALSE,FALSE,2019-07-17,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): yes,Long-term outcomes in immunologically low-risk kidney transplant recipients using tacrolimus.                Extension study of: Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study.,Netherlands,Erasmus Medical Center
main,EUCTR2019-004010-34-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004010-34,"Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia - a pilot, single-phase, II phase study - ClaTBI/2019",NA,NA,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>",No,Not applicable,No,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2020-05-18,16,"Accute myeloid leukemia <br>MedDRA version: 21.0Level: LLTClassification code 10028557Term: Myeloid leukemia, acuteSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]",FALSE,FALSE,2019-11-05,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,"Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia - a pilot, single-phase, II phase study",Poland,"Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie – Panstwowy Instytut Badawczy, Oddzial w Gliwicach"
covid,EUCTR2020-001296-33-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001296-33,"Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial",NA,Yes,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,Yes,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2020-05-06,80,"COVID-19 induced respiratory failure <br>MedDRA version: 20.0
Level: LLT
Classification code 10038696
Term: Respiratory failure (excl neonatal)
System Organ Class: 100000004855
 <br>MedDRA version: 20.0
Level: LLT
Classification code 10040050
Term: Sepsis NOS
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]",FALSE,FALSE,2020-04-03,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
","Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial",Denmark,"Section for Transfusion Medicine, Capital Region Blood bank, Copenhagen University Hospital"
covid,EUCTR2020-001310-38-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001310-38,"A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 - Convalescent Plasma against COVID-19",NA,NA,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: yes
Other trial design description: Cross-over allowed for patients with progressive COVID-19
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: Best supportive care
Number of treatment arms in the trial: 2
",Yes,Yes,No,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2020-04-06,120,"Patients with SARS-CoV-2 infection and:
1.	age = 18 years and = 75 years
2.	SARS-CoV-2 infection confirmed by PCR (BAL, sputum, nasal and/or pharyngeal 
                    swap)
3.	severe disease defined by at least one of the following:
  a.	respiratory rate = 30 breaths / minute under ambient air
  b.	requirement of any type of ventilation support
  c.	needs ICU treatment
 <br>MedDRA version: 20.1
Level: LLT
Classification code 10047475
Term: Viral pneumonia, unspecified
System Organ Class: 100000004862
 <br>MedDRA version: 23.0
Level: LLT
Classification code 10070267
Term: SARS virus test positive
System Organ Class: 100000004848
 <br>MedDRA version: 20.0
Level: LLT
Classification code 10021433
Term: Immunization
System Organ Class: 100000004865
 <br>MedDRA version: 21.1
Level: LLT
Classification code 10054540
Term: Passive immunization
System Organ Class: 100000004865
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",TRUE,FALSE,2020-03-31,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",Clinical Study to assess positive value of blood plasma from donors having built immunity against the new corona virus (SARS-CoV-2) transfused to patients suffering from SARS-CoV-2 infection,Germany,DRK-Bluspendedienst Baden-Württemberg - Hessen gGmbH
covid,EUCTR2020-001321-31-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001321-31,"Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUF",Treatment,NA,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: No comparator
Number of treatment arms in the trial: 3
",Yes,Yes,No,No,EUCTR,Phase 2,No,No,No,No,Yes,No,2020-04-11,165,Pneumonia due to SARS Cov2 (COVID-19);Therapeutic area: Diseases [C] - Virus Diseases [C02],FALSE,FALSE,2020-04-13,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",Clinical trial phase II to evaluate the efficacy of  3 types of treatment in patients with pneumonia by COVID-19,Spain,Hospital Universitario de Fuenlabrada
covid,EUCTR2020-001511-25-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001511-25,Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 - COL-COVID,NA,NA,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 2
",Yes,Yes,No,No,EUCTR,Phase 3,No,No,No,No,Yes,No,2020-04-14,102,COVID19;Therapeutic area: Body processes [G] - Immune system processes [G12],FALSE,FALSE,2020-04-15,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19,Spain,FFIS
covid,EUCTR2020-001635-27-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001635-27,"A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.",Treatment,NA,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 2
",Yes,Yes,No,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2020-05-04,NA,"Hospitalized Moderate and Severe COVID-19 Patients <br>MedDRA version: 20.0
Level: SOC
Classification code 10021881
Term: Infections and infestations
System Organ Class: 10021881 - Infections and infestations
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",FALSE,FALSE,2020-04-06,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",Evaluation of a combination of Masitinib and Isoquercetin in the Treatment of Hospitalized COVID-19 Patients.,France,AB Science
covid,EUCTR2020-001675-33-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001675-33,"A phase III, randomized, double-blind, placebo-controlled, multicentre, clinical trial to assess the efficacy and safety of VPM1002 in reducing hospital admissions and/or severe respiratory infectious diseases in elderly in the SARS-CoV-2 pandemic by modulating the immune system",NA,Yes,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,Yes,Yes,EUCTR,Phase 3,No,No,No,No,Yes,No,2020-05-29,2038,"infectious respiratory diseases (e.g. COVID-19) <br>MedDRA version: 20.0
Level: HLGT
Classification code 10024970
Term: Respiratory tract infections
System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]",TRUE,FALSE,2020-04-17,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",A study to investigate whether vaccination with VPM1002 can reduce elderly people's days with severe respiratory infectious diseases at hospital and/or at home,Germany,Vakzine Projekt Management GmbH
covid,EUCTR2020-001766-11-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001766-11,Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCE,Treatment,NA,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: group control
Number of treatment arms in the trial: 2
",Yes,Yes,No,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2020-04-29,90,Patients with Covid-19;Therapeutic area: Diseases [C] - Virus Diseases [C02],FALSE,FALSE,2020-04-15,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit,France,ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE
covid,EUCTR2020-001882-36-GR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001882-36,ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY: THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIAL,NA,NA,"Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
",No,Not applicable,No,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2020-05-07,90,"Management of infection by SARS-CoV-2 (COVID-19) <br>MedDRA version: 20.0
Level: LLT
Classification code 10035738
Term: Pneumonia viral NOS
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",FALSE,FALSE,2020-04-30,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",CLARITHROMYCIN IN COVID-19,Greece,Hellenic Institute for the Study of Sepsis
covid,EUCTR2020-002225-29-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002225-29,Evaluation of the effects of bradykinin antagonists on pulmonary manifestations of COVID-19 infections.,NA,NA,"Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: yes
Other: no
Number of treatment arms in the trial: 3
",Yes,Yes,Yes,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2020-11-12,45,"COVID positive patients with respiratory impairment <br>MedDRA version: 23.1
Level: LLT
Classification code 10084437
Term: COVID-19 PCR test positive
System Organ Class: 100000004848
 <br>MedDRA version: 23.1
Level: PT
Classification code 10084460
Term: COVID-19 treatment
System Organ Class: 10042613 - Surgical and medical procedures
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",FALSE,FALSE,2020-04-30,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",Evaluation of the effects of bradykinin antagonists on pulmonary manifestations of COVID-19 infections.,France,Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche
covid,EUCTR2020-002394-94-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002394-94,"Pulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild or
moderate corona virus disease (COVID-19)",Treatment,NA,"Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
",No,Not applicable,No,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2020-06-22,6,"Corona virus disease <br>MedDRA version: 23.0
Level: LLT
Classification code 10084355
Term: COVID-19 virus test positive
System Organ Class: 100000004848
 <br>MedDRA version: 23.0
Level: LLT
Classification code 10084383
Term: Novel COVID-19-infected pneumonia
System Organ Class: 100000004862
 <br>MedDRA version: 23.0
Level: LLT
Classification code 10084401
Term: COVID-19 respiratory infection
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]",FALSE,FALSE,2020-06-04,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
","Pulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild or
moderate corona virus disease (COVID-19)",Belgium,Dr. De Backer Wilfried BV
covid,EUCTR2020-002668-29-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002668-29,"A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX)

 - PEX in severe COVID-19",Treatment,NA,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: standard of care<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,No,Yes,EUCTR,Phase 2,No,No,No,No,Yes,No,2020-06-25,40,"COVID-19;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]",FALSE,FALSE,2020-06-10,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",plasma exchange in severe COVID-19 infection,United Kingdom,University College London
covid,EUCTR2020-002728-35-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002728-35,"An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia
- An open-label randomized controlled study -
",Treatment,NA,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: Supportive care (symptomatic therapy)<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,No,Yes,EUCTR,Phase 3,No,No,No,No,Yes,No,2020-09-17,150,"Patients with new type of coronavirus (SARS-CoV-2) infection proven by RT-PCR test  with mild pneumonia. <br>MedDRA version: 23.0
Level: PT
Classification code 10084268
Term: COVID-19
System Organ Class: 10021881 - Infections and infestations
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",FALSE,FALSE,2020-08-13,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",Clinical trial of Favipiravir treatment of patients with COVID-19,Hungary,Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium
covid,EUCTR2020-003368-24-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003368-24,"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19 - MK-4482 Ph 2/3 Study in Non-Hospitalized Adults with COVID-19",NA,Yes,"Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
",Yes,Yes,Yes,Yes,EUCTR,Phase 3,Yes,Yes,Yes,Yes,Yes,No,2020-10-05,1450,"COVID-19 <br>MedDRA version: 23.0
Level: LLT
Classification code 10084382
Term: Coronavirus disease 2019
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",TRUE,FALSE,2020-09-21,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",MK-4482 Ph 2/3 Study in Non-Hospitalized Participants with COVID-19,United States;Philippines;Spain;Ukraine;Chile;Israel;Russian Federation;Colombia;United Kingdom;Italy;France;Mexico;Canada;Brazil;South Africa;Germany;Sweden,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc."
covid,EUCTR2020-004123-16-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004123-16,"A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom",NA,NA,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: yes<br>Other trial design description: Observer-Blinded<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Yes,Yes,Yes,Yes,EUCTR,Phase 3,No,No,No,No,Yes,No,2020-09-23,15000,"Prevention of COVID-19 caused by SARS-CoV-2 <br>MedDRA version: 23.1
Level: LLT
Classification code 10084465
Term: COVID-19 vaccination
System Organ Class: 100000004865
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",FALSE,FALSE,2020-09-11,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",Study to evaluate the efficacy and safety of a SARS-CoV-2 rS vaccine with Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom,United Kingdom,"Novavax, Inc."
covid,IRCT20080901001165N48,http://en.irct.ir/trial/47318,Investigating the efficacy of Zofa (a herbal medicine) in symptom management of patients with COVID-19,Treatment,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block Randomization method is used to randomized the patients.",Yes,Yes,No,No,IRCT,Phase 3,No,No,No,Yes,No,No,2020-03-30,100,COVID-19. <br>Covid-19;U07.1,FALSE,FALSE,2020-04-22,3,Investigating the efficacy of Zofa (a herbal medicine) in symptom management of patients with COVID-19,Iran (Islamic Republic of),Niak pharmaceutical company
im,IRCT20090808002306N5,http://en.irct.ir/trial/41645,Comparative clinical trial of an evidence based and clinical pharmacist-recommended treatment protocol for the antimicrobial therapy of aspiration pneumonia in opioid overdosed patients with the current treatment practice in the poisonings referral University hospital of Khorshid,Treatment,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients with inclusion criteria will be randomly assigned to two groups of case and control using Research randomizer software.",Yes,Yes,No,No,IRCT,Phase 3,No,No,No,Yes,No,No,2019-11-09,80,"Aspiration pneumonia. <br>Lobar pneumonia, unspecified organism;J18.1",FALSE,FALSE,2019-11-30,3,The efficacy of recommended treatment protocol for the antimicrobial therapy of aspiration pneumonia in opioid overdosed patients,Iran (Islamic Republic of),Esfahan University of Medical Sciences
im,IRCT20100512003915N20,http://en.irct.ir/trial/31038,Effect of intratracheal budesonide with surfactant in  management of respiratory distress syndrome for prevention of bronchopulmonary dysplasia in preterm infants,Prevention,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: newborn infants who met study criteria randomly  allocate in two groups (surfactant and surfactant with budesonide) based on generated random number list, Blinding description: infants don't know the used drugs. clinical manager administer prepared drug according patients code. outcome is recorded by a nurse who is not aware administered drugs . researcher is blind about patients groups and records data.",Yes,Yes,Yes,No,IRCT,Phase 3,No,No,No,Yes,No,No,2018-04-16,128,Respiratory distress syndrome of newborn. <br>Respiratory distress syndrome of newborn,FALSE,FALSE,2018-07-07,3,Administration of budesonide with surfactant and prevention of bronchopulmonary dysplasia,Iran (Islamic Republic of),Tabriz University of Medical Sciences
main,IRCT20111107008022N5,http://en.irct.ir/trial/35126,Comparative bioequivalence study of two different Metformin 750mg formulations (Koushan pharmed & reference) in 24 Iranian volunteers,Other,NA,"Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Health service research, Randomization description: In the first period, the test and the reference drug are randomly divided into two groups of 12 (group A and B), then in the second period, in the cross over form, the groups A and B will be received reference and test drug, Blinding description: In this study, the volunteers, according to the predetermined random table that is available to the researcher, are in one of the groups receiving the test and reference drug. To blind the analyst and volunteers, the information collected from the drug concentration in the plasma of them is encoded and will be unlocked the codes after completion of the analysis.",Yes,Yes,Yes,No,IRCT,Undefined,No,No,No,Yes,No,No,2018-12-21,24,Health and normal volunteers. <br>--,FALSE,FALSE,2019-03-15,Bioequivalence,Bioequivalency study of two different Metformin formulations,Iran (Islamic Republic of),Kushan Pharmed  Company
main,IRCT20120215009014N308,http://en.irct.ir/trial/42604,The pregnancy success rate after frozen embryo transfer with and without intrauterine injection of HCG-activated peripheral blood mononuclear cells in infertile women: a single-blind randomized clinical trial,Treatment,NA,"Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients will be randomly assigned to intervention and control groups using block randomization. For this purpose, we will prepare four sheets of paper, writing on two sheets the name of the intervention and on the other two sheets the name of the control. The paper sheets will be pooled, placed in a container, and randomly drawn one at a time for each patient without replacement until all four sheets are drawn. The four paper sheets will be then placed back into the container, and this action repeated until the sample size is reached, Blinding description: The patients will be unaware of the type of intervention. Thus, the trial will be run as single-blind.",Yes,Yes,Yes,Yes,IRCT,Undefined,No,No,No,Yes,No,No,2019-10-23,92,Female infertility. <br>Female infertility,FALSE,FALSE,2019-10-13,N/A,The pregnancy success rate after frozen embryo transfer with and without intrauterine injection of HCG-activated peripheral blood mononuclear cells in infertile women,Iran (Islamic Republic of),Hamedan University of Medical Sciences
im,IRCT20130812014333N127,http://en.irct.ir/trial/39381,Comparison of the effect of epinephrine in combination with methylprednisolone on neurological complications and the need for vasopressor after resuscitation in patients with cardiopulmonary arrest,Treatment,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomly Individually by random number table via code receipt, Blinding description: In this study, participants and researchers are unaware and will be keep blinded to the allocation of study groups.",Yes,Yes,Yes,No,IRCT,Phase 3,No,No,No,Yes,No,No,2019-05-15,342,Cardiopulmonary arrest. <br>Cardiac arrest,FALSE,FALSE,2019-07-27,3,Comparison of the effect of epinephrine in combination with methylprednisolone on neurological complications  in patients with cardiopulmonary arrest,Iran (Islamic Republic of),Kermanshah University of Medical Sciences
im,IRCT20130917014693N9,http://en.irct.ir/trial/40932,Evaluation of a new protocol for controlling blood glucose and comparing it with old strategies for controlling blood glucose in patients who hospitalized in infectious ward,Treatment,NA,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.",Yes,No,No,No,IRCT,Phase 3,No,No,No,Yes,No,No,2017-04-04,108,Condition 1: Diabetes. Condition 2: Pneumonia. Condition 3: cellulitis. Condition 4: Diabetic foot infection. <br>Diabetes mellitus due to underlying condition <br>Streptococcus pneumoniae as the cause of diseases classified elsewhere <br>Cellulitis of toe <br>Personal history of diabetic foot ulcer;B95.3;L03.03;Z86.31,FALSE,FALSE,2019-08-15,3,Evaluation of a new protocol for controlling blood glucose in hospitalized patients,Iran (Islamic Republic of),Shahid Beheshti University of Medical Sciences
covid,IRCT20140911019125N6,http://en.irct.ir/trial/46668,Study the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia,Treatment,NA,"Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.",No,Not applicable,No,Yes,IRCT,Phase 2,No,No,No,Yes,No,No,2020-04-04,10,"Corona virus disease. <br>COVID19, virus identified;U07.1",FALSE,FALSE,2020-04-04,2,The effect of dental pulp mesenchymal stem cells in treatment of  corona disease,Iran (Islamic Republic of),Kerman University of Medical Sciences
covid,IRCT20151227025726N15,http://en.irct.ir/trial/48018,Evaluation the efficacy and safety of Umifenovir (Arbidol) Administration in comparison with Lopinavir-ritonavir (Kaletra) in COVID-19 patients,Treatment,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization method was used in this study. 25 blocks including 4 patients generated with online website. In each block, two patients will be assigned to Umifenovir group and two patients will be assigned to Lopinavir-ritonavir group.",Yes,Yes,No,No,IRCT,Phase 3,No,No,No,Yes,No,No,2020-04-08,100,"COVID-19 pneumonia. <br>COVID-19, virus identified;U07.1",FALSE,FALSE,2020-05-18,3,Evaluating the effects of Umifenovir (Arbidol) in COVID-19,Iran (Islamic Republic of),Shahid Beheshti University of Medical Sciences
covid,IRCT20160118026097N5,http://en.irct.ir/trial/48401,Evaluation of the effectiveness of plasmapheresis treatment in comparison with standard treatment in improving the symptoms of high-risk patients,Treatment,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: does not have.",Yes,Yes,No,No,IRCT,Phase 3,No,No,No,Yes,No,No,2020-03-29,60,"COVID19. <br>COVID-19, virus identified;U07.1",FALSE,FALSE,2020-09-19,3,Effect of plasmapheresis in the treatment of high-risk covid patients in Qom province,Iran (Islamic Republic of),Ghoum University of Medical Sciences
covid,IRCT20160131026298N4,http://en.irct.ir/trial/49925,Pilot clinical trial to evaluate the effectiveness of Herbal Cyclotide complex syrup as a prevention of disease complications in people exposed to COVID-19 virus,Prevention,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization will be by block randomization (quadruple random blocks). Randomization units are individuals. 60 outpatients referred to the hospital emergency department are allocated in one of the two intervention and control groupsaccording to  form of random string produced by online random allocation . This study is a non-concealed method and people in the intervention group will receive the intervention drug to prevent COVID-19 complications, but in the control group the drug is not used.",Yes,Yes,No,No,IRCT,Phase 3,No,No,No,Yes,No,No,2020-04-20,60,"COVID-19 viral disease. <br>Coronavirus infection, unspecified;B34.2",FALSE,FALSE,2020-08-04,2-3,Evaluation of the effectiveness of Cyclotide complex herbal syrup in preventing COVID-19 virus in exposed individuals,Iran (Islamic Republic of),Bagheiat-allah University of Medical Sciences
im,IRCT20160307026950N12,http://en.irct.ir/trial/39198,"Comparison of the effects of midazolam and dexmedetomidine on sedation levels, hemodynamics and complications in patients under brain stereotaxic surgery",Treatment,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: patients randomly assigned to two different groups A and B with Random Allocation computer software, Blinding description: patients and anesthetic technician did not know about administering drugs.",Yes,Yes,Yes,No,IRCT,Phase 3,No,No,No,Yes,No,No,2017-09-23,64,"Condition 1: respiratory apnea. Condition 2: systolic and diastolic blood pressure. Condition 3: heart rate. Condition 4: drug sedation level. Condition 5: bleeding. Condition 6: oxygen saturation level. <br>Apnea, not elsewhere classified <br>Hypotension due to drugs <br>Bradycardia, unspecified <br>Sedatives, hypnotics and antianxiety drugs <br>Haemorrhage and haematoma complicating a procedure, not elsewhere classified <br>Asphyxia and hypoxemia;R06.81;I95.2;R00.1;T81.0;R09.0",FALSE,FALSE,2019-06-06,3,The effects of midazolam and dexmedetomidine in patients under stereotaxic surgery,Iran (Islamic Republic of),Esfahan University of Medical Sciences
covid,IRCT20160310026998N11,http://en.irct.ir/trial/46690,Effect of metformin in COVID-19 mortality rate and symptom improvement,Treatment,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization generated with computer from 1 to 200. Computer will divide digits between two groups. According to the sequences of admission they will go to control or metformin group regarding computerized random list.",Yes,Yes,No,No,IRCT,Phase 3,No,No,No,Yes,No,No,2020-03-20,200,"corona virus or COVID-19. <br>Coronavirus infection, unspecified;B34.2",FALSE,FALSE,2020-03-27,3,Effect of metformin in COVID-19  symptom improvement and death,Iran (Islamic Republic of),Tabriz University of Medical Sciences
im,IRCT2016040316473N5,http://en.irct.ir/trial/15412,Comparing the effect of albumin and crystalloid serum as resuscitation fluid in survival of patients with severe sepsis shock,Treatment,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.",Yes,Yes,No,No,IRCT,Phase 3,No,No,No,Yes,No,No,2016-06-04,20,Septic shock. <br>Septic shock;Septic shock,FALSE,FALSE,2016-07-06,3,Comparing the effect of albumin and crystalloid serum as resuscitation fluid in survival of patients with severe sepsis shock,Iran (Islamic Republic of),"Vice chancellor for research, Tabriz University Of Medical Sciences."
im,IRCT2016052828134N1,http://en.irct.ir/trial/22888,Effects of Botanical mouthwash of Aloe Vera  on ventilator associated pneumonia of patients having Endotracheal tube hospitalized in the Intensive Care Unit,Prevention,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention.",Yes,Yes,Yes,No,IRCT,Phase 2,No,No,No,Yes,No,No,2016-01-30,79,Condition 1: Pneumonia. Condition 2: dental plaque. Condition 3: dental plaque. <br>Influenza and pneumonia <br>Deposits [accretions] on teeth <br>Caries of dentine;Influenza and pneumonia;Deposits [accretions] on teeth;Caries of dentine,FALSE,FALSE,2016-06-21,2,Effects of Botanical mouthwash of Aloe Vera  on ventilator associated pneumonia of patients having Endotracheal tube hospitalized in the Intensive Care Unit,Iran (Islamic Republic of),Research Deputy of Shahid Beheshti university of medical sciences
covid,IRCT20161206031256N3,http://en.irct.ir/trial/48329,Evaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19,Treatment,NA,"Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Crossover, Purpose: Treatment, Randomization description: Simple Randomization using the envelope placement method, Blinding description: Eligible patient will be randomized in 4 groups, two groups will receive interferon (alpha or beta) and two group will receive placebo. the subjects, investigator, and the data analysts will remain blinded.",Yes,Yes,Yes,No,IRCT,Phase 3,No,No,No,Yes,No,No,2020-05-23,76,COVID-19. <br>the code for the confirmed diagnosis of COVID-19;RA01.0.,FALSE,FALSE,2020-06-02,2-3,Using interferon to treat COVID-19,Iran (Islamic Republic of);Iran (Islamic Republic of),Mashhad University of Medical Sciences
covid,IRCT20170207032444N3,http://en.irct.ir/trial/47119,The efficacy and safety of Thalidomide in severe Covid19 pneumonia: Arandomized controlled clinical trial,Treatment,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization will be done. We use random allocation service for randomization. There is no allocation concealment.",Yes,Yes,No,No,IRCT,Phase 3,No,No,No,Yes,No,No,2020-04-15,60,COVID19. <br>disease diagnosis of COVID-19 confirmed by laboratory testing.;U07.1,FALSE,FALSE,2020-04-17,3,Thalidomide in COVID19,Iran (Islamic Republic of),Esfahan University of Medical Sciences
main,IRCT20171230038142N8,http://en.irct.ir/trial/38309,A Comparative Study on the Effect of Handmade Del Nido Cardioplegia Solution with Handmade St. Thomas Cardioplegia Solution in terms of Quantitative Levels of Cardiac Troponin I and Phosphocreatine kinase MB  in Ventricular Septal Defect Repair in Pediatric Cardiac Surgery.,Treatment,NA,"Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Female or male patients undergoing surgical repair of large-inferior ventricular diarrhea were easily and conveniently distributed in Chamran Hospital in Isfahan. Then they are randomly assigned random allocation and random numbers in two groups of 30, which will be used in a group of St. Thomas's handmade solution and in another group of Del NIDO solution, Blinding description: The samples are not aware of the therapeutic type and only the presenter is aware of the categorization of patients in each treatment group. Because these two solutions are injected during surgery, so patients are unaware of their drug type.",Yes,Yes,Yes,No,IRCT,Phase 3,No,No,No,Yes,No,No,2019-01-21,60,Ventricular Septal Defect Repair. <br>Ventricular septal defect as current complication following acute myocardial infarction,FALSE,FALSE,2019-03-16,2-3,The Effect of Handmade Del Nido Cardioplegia Solution with Handmade St. Thomas Cardioplegia Solution in terms of Quantitative Levels of Cardiac Troponin I and Phosphocreatine kinase MB.,Iran (Islamic Republic of),Esfahan University of Medical Sciences
im,IRCT20180826040877N1,http://en.irct.ir/trial/33535,Evaluation of the effect of intratracheal Salbutamol in addition to Surfactant on clinical course of neonates with respiratory distress syndrome with gestational age less than 34 weeks and 7 days and more than 1000 g weight,Treatment,NA,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.",Yes,No,No,No,IRCT,Undefined,No,No,No,Yes,No,No,2017-03-21,84,Respiratory distress syndrome. <br>Respiratory distress syndrome of newborn,FALSE,FALSE,2019-01-15,N/A,Salbutamol and neonatal respiratory distress syndrome,Iran (Islamic Republic of),Esfahan University of Medical Sciences
main,IRCT20180903040941N1,http://en.irct.ir/trial/33681,"The effect of  Matricaria chamomilla L. on insulin resistance, inflammatory status and other related indices in patients with non-alcoholic fatty liver",Treatment,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method: Simple randomization Random unit: Individual Randomization Tool: Random Numbers, Blinding description: Participants and researchers will not be aware of the study groups. Drug capsules and placebo capsules are also similar to each other and they are only labeled A and B.",Yes,Yes,Yes,Yes,IRCT,Undefined,No,No,No,Yes,No,No,2019-06-05,44,"non alcoholic fatty liver. <br>Fatty (change of) liver, not elsewhere classified;K76.0",FALSE,FALSE,2019-06-03,N/A,To evaluate effects of Matricaria chamomilla L. on patients with non alcoholic fatty liver disease,Iran (Islamic Republic of),Fasa University of Medical Sciences
covid,IRCT20180923041093N3,http://en.irct.ir/trial/46721,Efficacy of the myrtle (Myrtus Communis) syrup in the treatment of suspected novel coronavirus pneumonia (COVID-19),Treatment,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be selected according to the inclusion criteria and then randomly assigned to the experimental and control groups according to the random sequence obtained through random allocation software.",Yes,Yes,No,Yes,IRCT,Phase 3,No,No,No,Yes,No,No,2020-04-02,70,COVID-19. <br>COVID-19;U07.1,FALSE,FALSE,2020-03-28,3,Efficacy of the myrtle syrup in the treatment of novel corona,Iran (Islamic Republic of),Kerman University of Medical Sciences
im,IRCT20181109041596N1,http://en.irct.ir/trial/35097,"Evaluation of effect of fluoxetine on the clinical prognosis in patients with anterior ischemic optic neuropathy (AION) according to evaluations of visual acuity and VEP tests as main outcomes, in comparison between drug and placebo groups.",Treatment,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Other, Purpose: Treatment, Randomization description: In order to randomize allocation of patients in each group of study, we'll use the permuted block randomization method by means of blocks with 4 in size. According to the number of patients in each group of study (100 patients in each group), 25 blocks of four by means of online website  (www.sealedenvelope.com) will produce. For concealment, during randomization we'll use specific codes written on drug or placebo boxes which have been produced by computer. Each patient who enters the study will receive a box of drug or placebo according to the, Blinding description: During this study, participant will not be aware about if he receiving the drug or placebo because the shape and other features of boxes of both drugs and placebos are the same. The interviewer and investigator also will not be aware of which patients have received drug or place",Yes,Yes,Yes,No,IRCT,Phase 3,No,No,No,Yes,No,No,2018-12-22,100,"AION; Anterior ischemic optic neuropathy: is a condition in which the optic nerve is affected by ischemia at its anterior section (intraocular), AION has two types: arteritic and non arteritic types. arteritic type dominantly results from giant cell arteritis. The etiologies suggested for non arteritic type contains: diabetes mellitus, hypertension and obstructive sleep apnea. This research spends to non arteritic type of disease..",FALSE,FALSE,2019-01-07,3,Evaluation of effect of fluoxetine on the clinical prognosis in patients with anterior ischemic optic neuropathy (AION),Iran (Islamic Republic of),Iran University of Medical Sciences
main,IRCT20181207041876N1,http://en.irct.ir/trial/35752,"The effect of Caraway powder consumption on glycemic indices, lipid profile and Serum levels of nesfatin-1 in overweight and obese patients with type 2 diabetes",Treatment,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomization,permuted block randomization will be used with Fourth blocks. According to the 48-sampled sample size, 12 Fourth block will be produced using the online site (www.sealedenvelope.com), Blinding description: All capsules given to participants in the intervention and placebo groups are  same size and color, and all of the participants will not be informed about difference between the Caraway and  placebo capsules. This is performed by a non-researcher person such as Nurses or treatment staff and will not be informed about  difference between the Caraway and placebo capsules.",Yes,Yes,Yes,Yes,IRCT,Phase 3,No,No,No,Yes,No,No,2019-04-09,48,type 2 diabetes. <br>Type 2 diabetes mellitus without complications,FALSE,FALSE,2019-01-18,3,Effect of Caraway Powder consumption on the Treatment of Type 2 Diabetes,Iran (Islamic Republic of),Zahedan University of Medical Sciences
main,IRCT20190122042450N3,http://en.irct.ir/trial/38419,Comparison of the effect of empagliflozin and pioglitazone and placebo on liver steatosis change in fibroscan in diabetic patients with non-alcoholic fatty liver disease,Treatment,NA,"Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization method, 6 blocks, Blinding description: Abidi's pharmacy place the empagliflozine and pioglitazone and placebo in unique package and label as Q, M, Z and distribute between patients by non-notofied person while patient and investigator are not informed about type of drugs. Also, health-care and staffs of labroatory and radiology and fibroscan and DEXA are not informed about type of drugs. Also, Outcome evaluator and data analyzer are not informed about type of drugs.",Yes,Yes,Yes,No,IRCT,Phase 3,No,No,No,Yes,No,No,2019-05-21,105,Condition 1: Nonalcoholic fatty liver disease. Condition 2: Diabetes type 2. <br>Nonalcoholic steatohepatitis [NASH] <br>Type 2 diabetes mellitus;K75.81,FALSE,FALSE,2019-05-24,2-3,The effect of empagliflozin on nonalcoholic fatty liver disease in diabetic patients,Iran (Islamic Republic of),Iran University of Medical Sciences
main,IRCT20190410043236N1,http://en.irct.ir/trial/38837,Effect of vitamin D on improvement of left ventricular ejection fraction in patients with systolic heart failure,Treatment,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In present study, simple randomization method was used, Blinding description: This double-blind study was carried out and the cardiologist who do echocardiography patients, as well as those taking medication or placebo, are blind.",Yes,Yes,Yes,No,IRCT,Phase 3,No,No,No,Yes,No,No,2016-05-02,80,Condition 1: Systolic Heart failure. Condition 2: Systolic Heart failure. <br>IX Diseases of the circulatory system <br>Left ventricular failure;130-152;150.1,FALSE,FALSE,2019-07-08,2-3,Effect of vitamin D on improvement of left ventricular ejection fraction in patients with systolic heart failure,Iran (Islamic Republic of),Zanjan University of Medical Sciences
main,IRCT20190525043702N1,http://en.irct.ir/trial/39866,Effect of antiseptic and antibiotic usage within the implant on the pro-inflammatory cytokines interleukin 1ß and interleukin 6 in gingival crevicular fluid for the contact of the implant and abutment,Prevention,NA,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention.",Yes,No,No,No,IRCT,Undefined,No,No,No,Yes,No,No,2019-05-22,24,"Implantytis. <br>Unspecified complication of internal prosthetic device, implant and graft;T85.9",FALSE,FALSE,2019-06-05,N/A,Effect of antiseptic and antibiotic usage within the implant in gingival crevicular fluid for the contact of the implant and abutment,Iran (Islamic Republic of),Tabriz University of Medical Sciences
main,IRCT20191006044993N1,http://en.irct.ir/trial/42817,Comparison of the effect of plantago major with placebo on liver enzymes in patients with nonalcoholic fatty liver disease(NAFLD): a double-blind randomized clinical trial,Treatment,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The block randomization method is used using 4-way blocks and a random number table.Interventions A and B define six blocks of four.Using random numbers, we select and write blocks. Each individual is then assigned to an A or B intervention.For allocation concealment, sealed envelopes are used, so that the individual number is written on the envelope and the treatment group inside the envelope, Blinding description: The drug and placebo are coded in similar capsules and in identical packages, with the same color and aroma, and the patient, clinician, and researcher are unaware of how the drug or placebo is coded.",Yes,Yes,Yes,No,IRCT,Phase 3,No,No,No,Yes,No,No,2019-10-23,80,Non Alcoholic Fatty Liver Disease. <br>Non Alcoholic Fatty Liver Disease;K76-0,FALSE,FALSE,2019-11-05,2-3,Effect of Plantago major on nonalcoholic fatty liver disease,Iran (Islamic Republic of);Iran (Islamic Republic of),Iran University of Medical Sciences
covid,IRCT20200317046797N1,http://en.irct.ir/trial/46573,Effect of Camostate mesylate on clinical improvement and outcome of  Coronavirus (COVID-19)-induced pneumonia,Other,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: Simple randomization sequence will be generated with a computer from 1 to 40. The computer will divide the digits between the two groups. According to the sequence of admission, the patients will be allocated to the control or the Camostate mesylate groups regarding the sequence of computerized random list.",Yes,Yes,No,Yes,IRCT,Phase 3,No,No,No,Yes,No,No,2020-04-08,40,"Condition 1: Coronavirus (COVID-19)-induced pneumonia. Condition 2: COVID-19. <br>Other viral pneumonia <br>COVID-19, virus identified;J12.89;U07.1",FALSE,FALSE,2020-04-03,3,Effect of Camostate mesylate on the outcome of Coronavirus (COVID-19)-induced pneumonia,Iran (Islamic Republic of),Tabriz University of Medical Sciences
covid,IRCT20200324046850N3,http://en.irct.ir/trial/46718,The effect of naproxen on the healing process of patients with COVID-19,Treatment,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, block randomization was performed using block size: 6. Allocation sequence and concealment codes are generated by www.sealedenvelope.com. The closed envelope method was used to hide the allocation sequence, Blinding description: Participants and researchers in this study are blind, and the placebo used in the control group is the pill, which is similar in appearance and color to naproxen.",Yes,Yes,Yes,Yes,IRCT,Phase 3,No,No,No,Yes,No,No,2020-04-20,80,"corona virus disease. <br>COVID-19, virus not identified;U07.2",FALSE,FALSE,2020-03-30,3,The effect of naproxen on the healing process of patients with COVID-19,Iran (Islamic Republic of),Abadan University of Medical Sciences
covid,IRCT20200409047007N1,http://en.irct.ir/trial/47058,The effect of plasma administration of COVID-19 survivors in patients with acute respiratory distress syndrome due to COVID-19,Treatment,NA,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.",Yes,No,No,Yes,IRCT,Undefined,No,No,No,Yes,No,No,2020-04-13,64,COVID-19 Disease. <br>COVID-19 Disease;U07.02,FALSE,FALSE,2020-04-12,N/A,Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS,Iran (Islamic Republic of),Mashhad University of Medical Sciences
covid,IRCT20200518047497N1,http://en.irct.ir/trial/48289,Effect of Laris - Hyssop combined herbal distilled on the improving clinical and paraclinical symptoms in patients with COVID-19: A Randomized Controlled Trial,Treatment,NA,"Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be allocated to trial groups (intervention and placebo groups) randomly using Random Allocation Software (RAS) trough random block sizes of 4 and 6 with an allocation ratio of 1:1. Patients will receive a sealed bottle containing Laris-Hyssop distillate or placebo by giving 10 ml every 8 hours for 14 days. Random sequencing allocation will be produced by the person who has not to participate in the research. Bottles will be numbered from 1 to 80 according to the sequence generated. Both groups will receive routine treatments, Blinding description: This study is a randomized controlled triple blinded trial, meaning that the patients, researcher, and statistical analyst will be blind to the received active drug or placebo. Random sequencing allocation will be produced by the person who has not to participate in the research. Each",Yes,Yes,Yes,Yes,IRCT,Undefined,No,No,No,Yes,No,No,2020-05-25,80,COVID-19. <br>Novel Cronavirus Disease (COVID-19);U07.01,FALSE,FALSE,2020-05-21,N/A,Effect of Laris - Hyssop combined herbal distilled on the improving clinical and paraclinical symptoms in patients with COVID-19,Iran (Islamic Republic of);Iran (Islamic Republic of),Tabriz University of Medical Sciences
covid,IRCT20200705048011N1,http://en.irct.ir/trial/49481,The effect of garlic and cinnamon essential oil on the treatment of patients with  corona (COVID-19),Other,NA,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.",Yes,No,No,Yes,IRCT,Undefined,No,No,No,Yes,No,No,2020-08-22,45,"Covid-19. <br>Coronavirus infection, unspecified;B34.2",FALSE,FALSE,2020-08-16,N/A,Garlic and cinnamon on the treatment of patients with corona,Iran (Islamic Republic of),Sabzevar University of Medical Sciences
covid,IRCT20201004048922N1,http://en.irct.ir/trial/51443,Evaluation of the effectiveness of intravenous infusion of human COVID-19 hyperimmune plasma with specific antibody titer in hospitalized patients with Covid-19: a randomized clinical trial,Treatment,NA,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the Block Randomization method will be used. To perform, by visiting the site www.sealedenvelope.com, while entering the number of intervention groups, sample size, block size (which was selected according to the number of study groups, 6), a random list of patients in 3 groups will be obtained that this list will be used for random allocation of patients.",Yes,Yes,No,Yes,IRCT,Phase 3,No,No,No,Yes,No,No,2020-10-11,75,COVID-19. <br>Covid-19;U07.1,FALSE,FALSE,2020-10-10,3,Evaluation of the effectiveness of intravenous infusion of human COVID-19 hyperimmune plasma with specific antibody titer in hospitalized patients with Covid-19: a randomized clinical trial,Iran (Islamic Republic of),Tehran University of Medical Sciences
covid,IRCT20201016049048N1,http://en.irct.ir/trial/51767,Evaluation of the effectiveness of Iranian Borage Aerial Part infusion on the management of Covid-19 mild to moderate symptoms: a clinical trial,Treatment,NA,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization method will be blocked randomization (Quaternary random blocks). Randomization units are individuals. Sixty patients are randomly assigned to one of the two intervention and control groups using Random Allocation Software. This study is a double-blind method and patients in the intervention group will receive the intervention drug in addition to the routine treatment, but in the control group, they will receive the placebo in addition to the routine treatment, Blinding description: The study will be a double-blind trial and only the evaluator knows the results and the code of the intervention or control group. The containers of the drug and placebo are quite similar in appearance. The intervention and control groups will be separated by receiving a code.",Yes,Yes,Yes,Yes,IRCT,Phase 1,No,No,No,Yes,No,No,2020-11-07,60,"corona virus (covid-19). <br>COVID-19, virus identified;U07.1",FALSE,FALSE,2020-11-04,0 (exploratory trials),Effect of Iranian Borage on the management of Covid-19 symptoms,Iran (Islamic Republic of),Shiraz University of Medical Sciences
im,ISRCTN56992547,http://isrctn.com/ISRCTN56992547,Efficacy of Dexmedetomine versus Ketofol for sedation of postoperative mechanically ventilated patients with obstructive sleep apnea,Treatment,NA,Randomised parallel trial (Treatment),Yes,Yes,NA,No,ISRCTN,Undefined,Yes,No,No,No,No,No,2016-05-10,24,Obstructive sleep apnea <br>Respiratory <br>Obstructive sleep apnea,FALSE,FALSE,2017-04-12,Not Applicable,Efficacy of Dexmedetomine versus Ketofol for sedation of postoperative mechanically ventilated patients with obstructive sleep apnea,Egypt,Beni Suef University
main,JPRN-JapicCTI-194635,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194635,"A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Dose or Multiple Dose Study of KHK4323 in Healthy Volunteers, and Subjects with Atopic Dermatitis",NA,NA,"Double-Blind, Placebo-Controlled",Yes,Yes,Yes,Yes,JPRN,Phase 1,No,No,No,Yes,No,No,2019-02-22,120,Atopic dermatitis,FALSE,FALSE,2019-02-18,1,"A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Dose or Multiple Dose Study of KHK4323 in Healthy Volunteers, and Subjects with Atopic Dermatitis",Japan,"Kyowa Kirin Co., Ltd."
main,JPRN-JapicCTI-194721,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194721,A Phase I Multiple-Dose Study of RO7021610 in Japanese Patients with Ulcerative Colitis,NA,NA,"A randomized, double-blind, placebo-controlled, inter-individual dose-escalation study",Yes,Yes,Yes,Yes,JPRN,Phase 1,No,No,No,Yes,No,No,2019-06-01,24,Ulcerative colitis,FALSE,FALSE,2019-04-17,1,A Phase I Study of RO7021610 in Patients with Ulcerative Colitis,Japan,"Chugai Pharmaceutical Co., Ltd."
main,JPRN-jRCT2031190020,https://jrct.niph.go.jp/latest-detail/jRCT2031190020,Phase I study of pevonedistat in combination with capecitabine and oxaliplatin (CapeOX) in patients with advanced gastric cancer refractory to platinum - CaPevOX-1,Treatment,NA,"single arm study, open(masking not used), no treatment control, single assignment, treatment purpose",No,Not applicable,No,Yes,JPRN,Phase 1,No,No,No,Yes,No,No,2019-08-28,23,stomach cancer,FALSE,FALSE,2019-05-10,1,Phase I study of pevonedistat in combination with capecitabine and oxaliplatin (CapeOX) in patients with advanced gastric cancer refractory to platinum,Japan,Boku Narikazu
covid,JPRN-jRCT2031200180,https://jrct.niph.go.jp/latest-detail/jRCT2031200180,A Phase II/III Study of Sargramostim in Patients with Coronavirus Disease-2019 (COVID-19) - NPC-26-1,Treatment,NA,"randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose",Yes,Yes,Yes,Yes,JPRN,Phase 3,No,No,No,Yes,No,No,2020-11-24,60,Coronavirus disease-2019  (COVID-19) <br>Coronavirus,FALSE,FALSE,2020-11-04,2-3,A Phase II/III Study of Sargramostim,Japan,Taniguchi Masaki
main,JPRN-jRCT2063190013,https://jrct.niph.go.jp/latest-detail/jRCT2063190013,A phase I/IIa study of Ad-SGE-REIC-NS in patient with recurrent malignant glioma,Treatment,NA,"single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose",No,Not applicable,No,Yes,JPRN,Phase 2,No,No,No,Yes,No,No,2019-08-05,18,reccurent malignant glioma,FALSE,FALSE,2019-08-05,1-2,A phase I/IIa study of Ad-SGE-REIC-NS in patient with recurrent malignant glioma,Japan,Date Isao
main,JPRN-jRCTs031180097,https://jrct.niph.go.jp/latest-detail/jRCTs031180097,"JCOG1105: Randomized phase II study of two induction treatments of melphalan, prednisolone, plus bortezomib, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma - IMPROVE-MPB study",Treatment,NA,"randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose",Yes,Yes,No,No,JPRN,Phase 2,No,No,No,Yes,No,No,2013-07-22,90,Elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma,FALSE,FALSE,2019-01-28,2,"JCOG1105: Randomized phase II study of two induction treatments, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma",Japan,IIDA Shinsuke
main,JPRN-jRCTs031180139,https://jrct.niph.go.jp/latest-detail/jRCTs031180139,JCOG0601: Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma - NHL-R-CHOP-P2/3,Treatment,NA,"randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose",Yes,Yes,No,No,JPRN,Phase 3,No,No,No,Yes,No,No,2008-01-10,422,CD20 positive diffuse large B cell lmyphoma,FALSE,FALSE,2019-02-20,2-3,JCOG0601: Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma,Japan,ANDO Kiyoshi
main,JPRN-jRCTs031180183,https://jrct.niph.go.jp/latest-detail/jRCTs031180183,Phase 1 study of Disulfiram and Nivolumab for gastric cancer - Phase 1 study of Disulfiram and Nivolumab for gastric cancer,Treatment,NA,"single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose",No,Not applicable,No,Yes,JPRN,Phase 1,No,No,No,Yes,No,No,2019-04-03,16,Gastric cancer <br>gastric cancer,FALSE,FALSE,2019-03-05,1,Phase 1 study of Disulfiram and Nivolumab for gastric cancer,Japan,Shitara Kohei
im,JPRN-jRCTs031190084,https://jrct.niph.go.jp/latest-detail/jRCTs031190084,A phase II study of Atezolizumab for advanced / recurrent Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias - TORG1936 / AMBITIOUS study,Treatment,NA,"single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose",No,Not applicable,No,Yes,JPRN,Phase 2,No,No,No,Yes,No,No,2019-09-05,38,Advanced / recurrent Non-small cell lung cancer with idiopathic interstitial pneumonia,FALSE,FALSE,2019-08-27,2,TORG1936 / AMBITIOUS study,Japan,KATO Terufumi
im,JPRN-jRCTs041180086,https://jrct.niph.go.jp/latest-detail/jRCTs041180086,Clinical study about the safety of Orexin receptor antagonist Suvorexant for severe sleep apnea syndrome - Clinical study about the safety of Suvorexant for severe sleep apnea syndrome,Treatment,NA,"single arm study, open(masking not used), historical control, single assignment, treatment purpose",No,Not applicable,No,No,JPRN,Phase 4,No,No,No,Yes,No,No,2016-12-16,30,Sleep Apnea Syndrome,FALSE,FALSE,2019-03-12,4,Clinical study about the safety of Suvorexant for severe sleep apnea syndrome,Japan,Imaizumi Kazuyoshi
covid,JPRN-jRCTs051200036,https://jrct.niph.go.jp/latest-detail/jRCTs051200036,Efficacy and safety of nintedanib on lung fibrosis in severe pneumonia induced by coronavirus disease 2019: Historical control study.,Treatment,NA,"single arm study, open(masking not used), historical control, single assignment, treatment purpose",No,Not applicable,No,Yes,JPRN,Phase 2,No,No,No,Yes,No,No,2020-07-27,30,Severe pneumonia induced by COVID-19 <br>COVID-19;COVID-19,FALSE,FALSE,2020-07-27,2,Efficacy  of nintedanib on severe COVID-19 pneumonia.,Japan,Umemura Yutaka
im,JPRN-UMIN000023355,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025429,Effect of long-term clarithromycin antibiotic therapy on preventation of pneumonia in the elderly: a prospective randomised controlled trial. - Effect of long-term clarithromycin antibiotic therapy on preventation of pneumonia in the elderly: a prospective randomised controlled trial.,Prevention,NA,Parallel Randomized,Yes,Yes,NA,Yes,JPRN,Unreported,No,No,No,Yes,No,No,2016-12-08,200,pneumonia,FALSE,FALSE,2016-08-01,Not selected,Effect of long-term clarithromycin antibiotic therapy on preventation of pneumonia in the elderly: a prospective randomised controlled trial.,Japan,"Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine"
im,JPRN-UMIN000026129,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029759,The prospective study of nivolumab for advanced NSCLC patients with mild IIPs - The prospective study of nivolumab for advanced NSCLC patients with mild IIPs,NA,NA,Single arm Non-randomized,No,Not applicable,NA,No,JPRN,Unreported,No,No,No,Yes,No,No,2017-02-14,18,non-small cell lung cancerinterstitial lung diseaseinterstitial pneumonia,FALSE,FALSE,2017-02-15,Not selected,The prospective study of nivolumab for advanced NSCLC patients with mild IIPs,Japan,Kobe city medical center general hospital
im,JPRN-UMIN000031793,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036145,NA,NA,NA,Single arm Non-randomized,No,Not applicable,NA,No,JPRN,Unreported,No,No,No,Yes,No,No,2018-03-13,30,sleep apnea,FALSE,FALSE,2018-03-19,Not selected,An exploratory clinical study on the effects of SGLT2 inhibitors for type 2 diabetes (T2DM) patients with sleep apnea (SA),Japan,Juntendo University Graduate School of Medicine
im,JPRN-UMIN000035028,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039927,Effect and safety of Baloxavir Marboxil in children with influenza: multicenter randomized controlled study - Effect and safety of Baloxavir Marboxil in children with influenza: multicenter randomized controlled study,NA,Yes,Parallel Randomized,Yes,Yes,NA,Yes,JPRN,Unreported,No,No,No,Yes,No,No,2018-12-01,600,Influenza,FALSE,FALSE,2018-11-27,Not selected,Effect and safety of Baloxavir Marboxil in children with influenza: multicenter randomized controlled study,Japan,Kyoto Chubu Medical CenterDepartment of Pediatrics
main,JPRN-UMIN000035965,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040963,NA,NA,NA,Single arm Non-randomized,No,Not applicable,NA,No,JPRN,Unreported,No,No,No,Yes,No,No,2019-02-20,15,Glossodynia,FALSE,FALSE,2019-02-21,Not selected,The effects of Goreisan on pain perception in Glossodynia associate with dry mouth,Japan,Nagasaki University
main,JPRN-UMIN000037291,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042438,Exploring Mechanistic Study: Potential of Luseogliflozin on Restoration of Cardiomyocyte Energy Metabolism in Diabetic Patients with Coronary Artery Disease - EXPLORE-CAD,NA,NA,Parallel Randomized,Yes,Yes,NA,Yes,JPRN,Unreported,No,No,No,Yes,No,No,2019-08-01,80,Type 2 Diabetes,FALSE,FALSE,2019-07-05,Not selected,Exploring Mechanistic Study: Potential of Luseogliflozin on Restoration of Cardiomyocyte Energy Metabolism in Diabetic Patients with Coronary Artery Disease,Japan,Kumamoto University
main,KCT0003909,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=13801,Whole genomic landscape of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib,Treatment,NA,"Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable",No,Not applicable,No,Yes,KCT,Undefined,No,No,No,Yes,No,No,2019-05-30,148,;Neoplasms,FALSE,FALSE,2019-05-14,Not applicable,Whole genomic landscape of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib,"Korea, Republic of",Seoul National University Hospital
main,KCT0004211,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=14441,Optimal dose for topical use of tranexamic acid after cardiovascular surgery,Treatment,NA,"Primary Purpose : Treatment, Intervention Model : Parallel, Blinding/Masking : Double, Blinding Target : Subject, Investigator, Allocation : RCT",Yes,Yes,Yes,Yes,KCT,Phase 4,No,No,No,Yes,No,No,2019-09-02,123,;Diseases of the circulatory system,FALSE,FALSE,2019-08-19,Phase4,Optimal dose for topical use of tranexamic acid after cardiovascular surgery,"Korea, Republic of",Korea University Anam Hospital
im,NCT02708173,https://clinicaltrials.gov/show/NCT02708173,NA,Prevention,NA,"Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention",No,Not applicable,No,No,CT.gov,Phase 1,No,No,No,Yes,No,No,2016-03-01,40,Quadrivalent Influenza Virus Vaccine,FALSE,TRUE,2016-03-10,Phase 1,Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older,China,Beijing Chaoyang District Centre for Disease Control and Prevention
im,NCT02774044,https://clinicaltrials.gov/show/NCT02774044,Evaluating the Efficacy and Safety of an Innovative and Affordable Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates: a Multi-site Randomized Clinical Trial,Treatment,NA,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment",Yes,Yes,Yes,Yes,CT.gov,Phase 3,NA,NA,NA,NA,NA,NA,2016-06-01,900,Respiratory Distress Syndrome,FALSE,TRUE,2016-05-10,Phase 2/Phase 3,Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates,NULL,Ramesh K Agarwal
im,NCT02809209,https://clinicaltrials.gov/show/NCT02809209,"A Phase 1 Double Blinded, Randomized, Placebo Controlled Study in Vietnamese Healthy Adult Volunteers to Assess the Safety and Immunogenicity of a Seasonal Trivalent Inactivated Split Vision Influenza Vaccine (IVACFLU-S) Produced by IVAC",Prevention,NA,"Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention",Yes,Yes,Yes,No,CT.gov,Phase 1,No,No,No,Yes,No,No,2015-10-01,30,Influenza,FALSE,TRUE,2016-05-31,Phase 1,Safety of the Seasonal Trivalent Inactivated Split Virion Influenza Vaccine (IVACFLU-S),Vietnam,"National Institute of Hygiene and Epidemiology, Vietnam"
im,NCT02987374,https://clinicaltrials.gov/show/NCT02987374,Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization,Other,NA,Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,No,Not applicable,No,No,CT.gov,Phase 4,NA,NA,NA,NA,NA,NA,2012-05-01,10,Influenza;Influenza;Influenza;Influenza,FALSE,TRUE,2016-12-06,Phase 4,Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization,NULL,Stanford University
im,NCT03020498,https://clinicaltrials.gov/show/NCT03020498,Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire - Years 2 (2010) & 3 (2011),Other,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 4,NA,NA,NA,NA,NA,NA,2010-09-01,91,Influenza;Influenza;Influenza,FALSE,TRUE,2017-01-11,Phase 4,B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011),NULL,Stanford University
im,NCT03020537,https://clinicaltrials.gov/show/NCT03020537,"U19 Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire- Year 5, 2013",Other,NA,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Yes,No,No,No,CT.gov,Phase 4,NA,NA,NA,NA,NA,NA,2013-10-01,8,Influenza;Influenza;Influenza,FALSE,TRUE,2017-01-11,Phase 4,"B-cell Immunity to Influenza (SLVP017)- Year 5, 2013",NULL,Stanford University
im,NCT03068741,https://clinicaltrials.gov/show/NCT03068741,Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP),Treatment,NA,"Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 4,No,Yes,No,No,No,No,2020-03-23,2040,Severe Sepsis or Septic Shock,FALSE,FALSE,2017-02-06,Phase 4,Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP),Canada,Dr. Damon Scales
im,NCT03122639,https://clinicaltrials.gov/show/NCT03122639,Vascular Endothelial Activation in Obstructive Sleep Apnea,Other,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 1,No,Yes,No,No,No,No,2017-09-01,245,Obstructive Sleep Apnea of Adult,FALSE,FALSE,2017-04-12,Early Phase 1,Endothelial Function in Obstructive Sleep Apnea,United States,Columbia University
im,NCT03143101,https://clinicaltrials.gov/show/NCT03143101,A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age,Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 4,No,Yes,No,No,No,No,2017-05-08,200,Influenza;Healthy;Influenza;Healthy;Influenza;Healthy;Influenza;Healthy,FALSE,FALSE,2017-05-04,Phase 4,Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age,United States;United States;United States;United States;United States,MedImmune LLC
im,NCT03160118,https://clinicaltrials.gov/show/NCT03160118,A Clinical Study of Biomarkers of Innate and Adaptive Immune Activation Associated With Symptoms and Immune Responses After Administration of a Single Dose of a Quadrivalent Inactivated Split Virus Influenza Vaccine to Healthy Young Adults.,Other,NA,Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 4,No,No,No,No,Yes,No,2017-03-27,20,Prevention of Influenza;Prevention of Influenza;Prevention of Influenza;Prevention of Influenza,FALSE,FALSE,2017-03-24,Phase 4,Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults,Belgium;Belgium;Belgium;Belgium;Belgium,"University Hospital, Ghent"
im,NCT03186742,https://clinicaltrials.gov/show/NCT03186742,Effects of Eplerenone on Left Ventricular Hypertrophy in Patients With Resistant Hypertension and Obstructive Sleep Apnoea,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 4,NA,NA,NA,NA,NA,NA,2014-07-01,125,"Hypertension,Essential;Obstructive Sleep Apnea;Left Ventricular Hypertrophy;Hypertension,Essential;Obstructive Sleep Apnea;Left Ventricular Hypertrophy;Hypertension,Essential;Obstructive Sleep Apnea;Left Ventricular Hypertrophy;Hypertension,Essential;Obstructive Sleep Apnea;Left Ventricular Hypertrophy",FALSE,FALSE,2017-06-10,Phase 4,Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy,NULL,Poznan University of Medical Sciences
im,NCT03208361,https://clinicaltrials.gov/show/NCT03208361,Efficacy of High Doses of Oral Penicillin V Versus High Doses of Oral Amoxicillin in the Treatment of Non-severe Community-acquired Pneumonia in Adults,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,NA,CT.gov,Phase 3,No,No,No,No,Yes,No,2013-11-05,43,Community-acquired Pneumonia (CAP);Community-acquired Pneumonia (CAP);Community-acquired Pneumonia (CAP);Community-acquired Pneumonia (CAP),EUCTR2012-003511-63-ES,FALSE,2017-06-26,Phase 3,Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.,Spain;Spain;Spain;Spain;Spain,Jordi Gol i Gurina Foundation
im,NCT03275415,https://clinicaltrials.gov/show/NCT03275415,Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study,Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 4,NA,NA,NA,NA,NA,NA,2018-10-01,380,Respiratory Distress Syndrome;Bronchopulmonary Dysplasia,FALSE,FALSE,2017-09-05,Phase 4,Intratracheal Budesonide/Surfactant Prevents BPD,NULL,Taipei Medical University
im,NCT03282240,https://clinicaltrials.gov/show/NCT03282240,Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older,Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Outcomes Assessor).",Yes,Yes,Yes,No,CT.gov,Phase 3,No,Yes,No,No,No,No,2017-09-08,2670,Influenza,FALSE,FALSE,2017-09-12,Phase 3,Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants =65 Years in the US,United States;United States;United States,"Sanofi Pasteur, a Sanofi Company"
im,NCT03330132,https://clinicaltrials.gov/show/NCT03330132,Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial,Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).",Yes,Yes,Yes,No,CT.gov,Phase 4,No,No,No,Yes,No,No,2017-10-07,1861,"Influenza, Human",FALSE,FALSE,2017-10-10,Phase 4,Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong,China;China;China,The University of Hong Kong
im,NCT03337373,https://clinicaltrials.gov/show/NCT03337373,The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients,Other,NA,Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 4,No,No,No,Yes,No,No,2017-12-15,10,"Critical Illness;Respiratory Distress Syndrome, Adult;Neuromuscular Blockade;Respiratory Failure;Paralysis;ARDS, Human",FALSE,FALSE,2017-11-02,Phase 4,The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium,Thailand,Mahidol University
im,NCT03380507,https://clinicaltrials.gov/show/NCT03380507,"Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock",Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 3,No,No,No,Yes,No,No,2018-03-17,212,Septic Shock;Critical Illness,FALSE,FALSE,2017-12-07,Phase 2/Phase 3,"Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock",Qatar,Hamad Medical Corporation
im,NCT03383887,https://clinicaltrials.gov/show/NCT03383887,Effect of DAW1033D on Obstructive Sleep Apnea and Its Phenotypic Traits,Treatment,NA,"Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2017-12-13,11,Obstructive Sleep Apnea (OSA),FALSE,FALSE,2017-12-13,Phase 1/Phase 2,DAW1033D in Obstructive Sleep Apnea,United States,Brigham and Women's Hospital
im,NCT03441373,https://clinicaltrials.gov/show/NCT03441373,"Clinical Study to Assess Efficacy, Safety, Tolerability and Optimal Dose Ranging of XC8 in Doses 20, 100 and 200 mg Once Daily in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections (ARVI)",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Yes,Yes,Yes,No,CT.gov,Phase 3,No,No,No,No,Yes,No,2016-02-03,320,Influenza;Acute Respiratory Infection,FALSE,FALSE,2018-02-14,Phase 2/Phase 3,XC8 in the Treatment of Patients With Acute Respiratory Viral Infection,Russian Federation,PHARMENTERPRISES LLC
im,NCT03453801,https://clinicaltrials.gov/show/NCT03453801,"The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection",Other,NA,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Yes,No,No,No,CT.gov,Phase 1,No,Yes,No,No,No,No,2014-09-30,80,Influenza;Healthy,FALSE,FALSE,2018-02-27,Phase 1,"The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection",United States,Stanford University
im,NCT03454217,https://clinicaltrials.gov/show/NCT03454217,Impact of Tramadol and Oxycodone on Sleep Apnea,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 4,No,No,No,No,Yes,No,2018-02-27,60,Sleep Apnea,FALSE,FALSE,2018-02-27,Phase 4,Impact of Tramadol and Oxycodone on Sleep Apnea,Switzerland,Centre Hospitalier Universitaire Vaudois
im,NCT03459391,https://clinicaltrials.gov/show/NCT03459391,"A Double-blind, Randomized, Placebo-controlled Study of the Safety,Tolerability and Pharmacokinetics of Increasing Doses of XC221 After Single and Repeated Oral Administration in Healthy Volunteers",Treatment,NA,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Yes,Yes,Yes,No,CT.gov,Phase 1,No,No,No,No,Yes,No,2017-05-22,32,Influenza;Acute Respiratory Infection;Influenza;Acute Respiratory Infection;Influenza;Acute Respiratory Infection,FALSE,FALSE,2018-02-26,Phase 1,"Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers",Russian Federation;Russian Federation;Russian Federation;Russian Federation;Russian Federation;Russian Federation,PHARMENTERPRISES LLC
im,NCT03489018,https://clinicaltrials.gov/show/NCT03489018,The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines (PCV10 and PCV13) on Immunogenicity and Vaccine-serotype Carriage in Kenyan Infants,Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 4,Yes,No,No,No,No,No,2019-03-21,2100,"Pneumococcal Infection;Streptococcus Pneumoniae Infection;Invasive Pneumococcal Disease, Protection Against",FALSE,FALSE,2018-03-29,Phase 4,The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants,Kenya,London School of Hygiene and Tropical Medicine
im,NCT03530124,https://clinicaltrials.gov/show/NCT03530124,Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines,Prevention,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 4,No,Yes,No,No,No,No,2018-07-17,300,Apnea;Apnea Neonatal;Prematurity,FALSE,FALSE,2018-05-08,Phase 4,Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines,United States,Duke University
im,NCT03581903,https://clinicaltrials.gov/show/NCT03581903,A Phase I Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine,Prevention,NA,Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).,No,Not applicable,No,No,CT.gov,Phase 1,No,Yes,No,No,No,No,2017-09-19,20,Influenza,FALSE,FALSE,2018-06-26,Phase 1,A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine,United States,National Institute of Allergy and Infectious Diseases (NIAID)
im,NCT03592277,https://clinicaltrials.gov/show/NCT03592277,Vitamins B1 and C to Improve Outcomes in Patients With Severe Sepsis,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2018-09-14,120,Sepsis;Septic Shock,FALSE,FALSE,2018-06-18,Phase 2,Vitamin C & Thiamine in Sepsis,United States,Saint Francis Care
im,NCT03607071,https://clinicaltrials.gov/show/NCT03607071,Outcome of Myocardial Inflammation After Steroid Therapy in Thai Systemic Sclerosis Patients: an Open Label Study,Treatment,NA,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,No,CT.gov,Phase 2,No,No,No,Yes,No,No,2018-05-15,20,Myocardial Inflammation,FALSE,FALSE,2018-07-20,Phase 2,Outcome of Steroid Therapy for Myocardial Inflammation in Scleroderma,Thailand,Khon Kaen University
im,NCT03608514,https://clinicaltrials.gov/show/NCT03608514,Terlipressin Alone Versus the Standard Therapy With Catecholamines for Hepatic Patients With Septic Shock- Prospective Single Center Randomized Controlled Study.,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).,Yes,Yes,Yes,No,CT.gov,Phase 3,Yes,No,No,No,No,No,2018-07-01,100,Resolution of Septic Shock With Terlipressin,FALSE,FALSE,2018-07-12,Phase 2/Phase 3,Terlipressin Alone Versus the Standard Therapy With Catecholamines for Hepatic Patients With Septic Shock- Prospective Single Center Randomized Controlled Study.,Egypt,National Hepatology & Tropical Medicine Research Institute
im,NCT03614975,https://clinicaltrials.gov/show/NCT03614975,Immunologic Response to Influenza Vaccination in Children and Adolescents: A RCT Trial of Influenza Vaccines,Prevention,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 4,No,Yes,No,No,No,No,2018-09-13,166,"Influenza, Human;Immune Response",FALSE,FALSE,2018-06-06,Phase 4,Immunologic Response to Influenza Vaccination in Children and Adolescents,United States,Richard Zimmerman MD
im,NCT03640052,https://clinicaltrials.gov/show/NCT03640052,Pharmacological Activation of Hypoglossal Motor Nucleus for Obstructive Sleep Apnea,Treatment,NA,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2018-10-30,10,Obstructive Sleep Apnea,FALSE,FALSE,2018-08-17,Phase 1/Phase 2,Pharmacological Activation of HMN for OSA,United States,Brigham and Women's Hospital
im,NCT03657719,https://clinicaltrials.gov/show/NCT03657719,"Open-labeled(Part 1), Single-group(Part 2), Randomized(Part 2), Double-blind(Part 2), Active-controlled(Part 2) Pharse II Clinical Trial to Evaluate Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects",Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,No,No,Yes,No,No,2018-10-01,105,"Influenza, Human",FALSE,FALSE,2018-08-27,Phase 2,A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects,"Korea, Republic of",Green Cross Corporation
im,NCT03690583,https://clinicaltrials.gov/show/NCT03690583,Assessment of the Immunomodulatory Effect of Zinc Supplementation on the Clinical Evolution of Children With Pneumonia,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).",Yes,Yes,Yes,No,CT.gov,Phase 1,No,No,Yes,No,No,No,2014-01-29,103,"Pneumonia;Children, Only;Pneumonia;Children, Only",FALSE,FALSE,2018-09-20,Phase 1,Immunomodulation by Zinc Supplementation in Children With Pneumonia,Mexico;Mexico,Universidad Nacional Autonoma de Mexico
im,NCT03694808,https://clinicaltrials.gov/show/NCT03694808,Non-inferiority Study of Adjuvanted vs. High Dose Flu Vaccine in Residents of Long Term Care,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).,Yes,Yes,Yes,No,CT.gov,Phase 4,No,Yes,No,No,No,No,2018-09-23,500,Flu,FALSE,FALSE,2018-09-26,Phase 4,FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care,United States,David H. Canaday
im,NCT03782259,https://clinicaltrials.gov/show/NCT03782259,Effects of SGLT-2 Inhibition With Dapagliflozin on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI With T1- and T2-mapping in Patients With Type-2 Diabetes,Other,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Screening. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 4,No,Yes,No,No,No,No,2019-02-26,60,Type 2 Diabetes Mellitus;Myocardial Fibrosis;Myocardial Inflammation,FALSE,FALSE,2018-10-24,Phase 4,Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2,United States,University of Washington
main,NCT03803540,https://clinicaltrials.gov/show/NCT03803540,"Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis, a Pilot Study.",Treatment,NA,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 1,No,No,No,No,Yes,No,2019-05-01,15,Non-Alcoholic Fatty Liver Disease;Non Alcoholic Steatohepatitis,FALSE,FALSE,2019-01-09,Phase 1,Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis,Spain,Puerta de Hierro University Hospital
main,NCT03805568,https://clinicaltrials.gov/show/NCT03805568,The Effect of Dexmedetomidine and Remifentanil on the Postoperative Sore Throat After Thyroidectomy,Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).",Yes,Yes,Yes,No,CT.gov,Undefined,No,No,No,Yes,No,No,2017-07-05,74,Post Operative Sore Throat,FALSE,FALSE,2019-01-07,N/A,A Postoperative Sore Throat After Thyroidectomy,"Korea, Republic of",Yeungnam University College of Medicine
main,NCT03813121,https://clinicaltrials.gov/show/NCT03813121,The Effects of Sedatives on Tobacco Use Disorder,Other,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Single (Participant).,Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2019-06-01,20,Tobacco Use Disorder,FALSE,FALSE,2019-01-18,Phase 1/Phase 2,The Effects of Sedatives on Tobacco Use Disorder,United States,University of Arkansas
main,NCT03815929,https://clinicaltrials.gov/show/NCT03815929,Impact of Individualized Estrogen Therapy on Cardiovascular Disease Risk Parameters in Young Women After Bilateral Oophorectomy: A Randomized Controlled Trial,Prevention,NA,Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2019-03-15,60,Cardiovascular Risk Reduction,FALSE,FALSE,2019-01-17,Phase 2,"Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women",United States,Mayo Clinic
im,NCT03816878,https://clinicaltrials.gov/show/NCT03816878,"An Exploration of a Prime-Boost Approach for Universal Influenza Vaccination: Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals",Prevention,NA,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Yes,No,No,No,CT.gov,Phase 1,No,Yes,No,No,No,No,2019-01-08,35,Influenza,FALSE,FALSE,2019-01-23,Phase 1,"Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals",United States,National Institute of Allergy and Infectious Diseases (NIAID)
main,NCT03835949,https://clinicaltrials.gov/show/NCT03835949,A Phase 1 Dose-Escalation Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer,Treatment,NA,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 1,No,Yes,No,No,No,No,2019-07-26,36,Solid Tumor;Metastatic Cancer,FALSE,FALSE,2019-02-05,Phase 1,Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer,United States,Tracon Pharmaceuticals Inc.
main,NCT03841110,https://clinicaltrials.gov/show/NCT03841110,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1),Treatment,NA,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,No,No,Yes,CT.gov,Phase 1,No,Yes,No,No,No,No,2019-02-15,76,Advanced Solid Tumors;Lymphoma;Gastric Cancer;Colorectal Cancer;Head and Neck Cancer;Squamous Cell Carcinoma;EGFR Positive Solid Tumor;HER2-positive Breast Cancer;Hepatocellular Carcinoma;Small Cell Lung Cancer;Renal Cell Carcinoma;Pancreas Cancer;Melanoma;NSCLC;Urothelial Carcinoma;Cervical Cancer;Microsatellite Instability;Merkel Cell Carcinoma,FALSE,FALSE,2019-02-12,Phase 1,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors,United States,Fate Therapeutics
im,NCT03845231,https://clinicaltrials.gov/show/NCT03845231,Mucosal Correlates of Protection After Influenza Viral Challenge of Vaccinated and Unvaccinated Healthy Volunteers,Other,NA,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Yes,No,No,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2019-04-29,82,Influenza,FALSE,FALSE,2019-02-16,Phase 2,Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route,United States,National Institute of Allergy and Infectious Diseases (NIAID)
main,NCT03856164,https://clinicaltrials.gov/show/NCT03856164,Use of Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery,Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,No,Yes,No,No,No,No,2019-06-17,110,Post Partum Hemorrhage;Fibrinolysis; Hemorrhage;Blood Loss,FALSE,FALSE,2019-02-21,Phase 2/Phase 3,Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery,United States,University of Texas Southwestern Medical Center
main,NCT03863938,https://clinicaltrials.gov/show/NCT03863938,"A Randomized, Open-label, Single-dose Phase 1 Clinical Trial to Compare the Effect of Timing of Food on the Pharmacokinetics and Pharmacodynamics of K-CAB (Tegoprazan) in Healthy Male Subjects",Treatment,NA,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 1,No,No,No,Yes,No,No,2019-03-27,12,Healthy,FALSE,FALSE,2019-02-28,Phase 1,Food-Effect on PK and PD of Single Oral Dose of Tegoprazan in Healthy Male Subjects,"Korea, Republic of",CJ HealthCare Corporation
main,NCT03868423,https://clinicaltrials.gov/show/NCT03868423,Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes,Treatment,NA,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2019-03-20,20,Advanced Malignant Neoplasm;ALK Fusion Protein Expression;ALK Gene Amplification;ALK Gene Mutation;Locally Advanced Malignant Solid Neoplasm;Metastatic Malignant Neoplasm in the Brain;Metastatic Malignant Neoplasm in the Central Nervous System;Metastatic Malignant Solid Neoplasm;ROS1 Fusion Positive;ROS1 Gene Amplification;ROS1 Gene Mutation,FALSE,FALSE,2019-02-04,Phase 2,Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers,United States,Sameek Roychowdhury
main,NCT03876210,https://clinicaltrials.gov/show/NCT03876210,"A Randomized, Open-label, Single Dose, 2x2 Crossover Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination or Loose Combination of PK101 in Healthy Volunteers",Treatment,NA,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 1,No,No,No,Yes,No,No,2019-07-12,47,Arthritis,FALSE,FALSE,2019-03-13,Phase 1,Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs,"Korea, Republic of","PMG Pharm Co., Ltd"
im,NCT03898973,https://clinicaltrials.gov/show/NCT03898973,Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood,Other,NA,Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 4,NA,NA,NA,NA,NA,NA,2019-06-01,50,Influenza,FALSE,TRUE,2019-03-30,Phase 4,Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood,NULL,Stanford University
im,NCT03900988,https://clinicaltrials.gov/show/NCT03900988,"A Randomized, Double Blind, Placebo Controlled Trial of Intravenous N-acetylcysteine and Oseltamivir Versus Intravenous 5% Dextrose and Oseltamivir in Adults Hospitalized With Influenza Complicated by Lower Respiratory Tract Infection.",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 4,NA,NA,NA,NA,NA,NA,2020-10-01,160,Influenza,FALSE,FALSE,2019-03-31,Phase 4,Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia,NULL,Chinese University of Hong Kong
main,NCT03904199,https://clinicaltrials.gov/show/NCT03904199,A Prospective Randomized Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients With Hyperglycemia,Other,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 4,No,Yes,No,No,No,No,2019-04-04,576,Hyperglycemia,FALSE,FALSE,2019-04-03,Phase 4,Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia,United States,H. Lee Moffitt Cancer Center and Research Institute
main,NCT03904836,https://clinicaltrials.gov/show/NCT03904836,Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session,Other,NA,Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,No,Not applicable,No,No,CT.gov,Phase 1,No,Yes,No,No,No,No,2019-01-31,12,"Renal Dialysis;Renal Failure, Chronic",FALSE,FALSE,2019-02-08,Phase 1,Tobramycin Administered at the Beginning of Dialysis,Canada,Maisonneuve-Rosemont Hospital
im,NCT03911440,https://clinicaltrials.gov/show/NCT03911440,Diagnosis and Treatment of Mycoplasma Pneumoniae and Vaccine Development,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Undefined,No,No,No,Yes,No,No,2018-11-10,100,Atypical Pneumonia,FALSE,FALSE,2019-04-09,N/A,Treatment and Vaccine Development of Mycoplasma Pneumoniae,Taiwan,National Taiwan University Hospital
im,NCT03911817,https://clinicaltrials.gov/show/NCT03911817,Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients,Other,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: Single (Participant).,Yes,Yes,Yes,No,CT.gov,Phase 4,Yes,No,No,No,No,No,2017-11-15,60,Septic Shock,FALSE,FALSE,2019-04-09,Phase 4,Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients,Egypt,Ain Shams University
main,NCT03913559,https://clinicaltrials.gov/show/NCT03913559,Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia,Treatment,NA,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2019-05-14,32,Acute Lymphoblastic Leukemia,FALSE,FALSE,2019-04-09,Phase 2,Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia,United States,St. Jude Children's Research Hospital
main,NCT03926377,https://clinicaltrials.gov/show/NCT03926377,Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid,Treatment,NA,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,No,CT.gov,Phase 4,NA,NA,NA,NA,NA,NA,2019-04-01,50,Osteoporosis;Bullous Pemphigoid,FALSE,TRUE,2019-04-15,Phase 4,Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid,NULL,"Centre Hospitalier Universitaire, Amiens"
main,NCT03927781,https://clinicaltrials.gov/show/NCT03927781,Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot,Treatment,NA,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,No,CT.gov,Phase 3,No,Yes,No,No,No,No,2019-04-01,10,"Nephrolithiasis;Urolithiasis;Perioperative/Postoperative Complications;Pain, Postoperative;Pain, Acute;Anesthesia;Urologic Diseases;Anesthesia Morbidity",FALSE,FALSE,2019-04-22,Phase 3,Perioperative Pregabalin in Ureteroscopy: a Pilot,United States,University of Missouri-Columbia
main,NCT03931135,https://clinicaltrials.gov/show/NCT03931135,Comparison Between Cyclizine and Dexamethasone for Prevention of Nausea and Vomiting After Intrathecal Morphine in Patients Undergoing Cesarean Section,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Undefined,NA,NA,NA,NA,NA,NA,2019-09-01,160,Spinal Anesthetics Causing Adverse Effects in Therapeutic Use,FALSE,FALSE,2019-03-26,N/A,Cyclizine Vs. Dexamethasone for Nausea and Vomiting Following Intrathecal Morphine in Cases of Cesarean Section,NULL,Assiut University
main,NCT03958097,https://clinicaltrials.gov/show/NCT03958097,A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer,Treatment,NA,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,No,CT.gov,Phase 2,No,No,No,Yes,No,No,2019-05-17,20,Non-small Cell Lung Cancer,FALSE,FALSE,2019-05-20,Phase 2,A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer,China,First Hospital of Jilin University
im,NCT03958396,https://clinicaltrials.gov/show/NCT03958396,The Pharmacokinetic and Pharmacodynamics Profiles of Remifentanil in Children With Obstructive Sleep Apnea.,Treatment,NA,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,No,No,No,CT.gov,Phase 1,NA,NA,NA,NA,NA,NA,2015-09-01,30,Obstructive Sleep Apnea,FALSE,FALSE,2019-05-16,Early Phase 1,Remifentanil in Children With Obstructive Sleep Apnea,NULL,Washington University School of Medicine
main,NCT03961308,https://clinicaltrials.gov/show/NCT03961308,"A Phase 1, Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Autoinjector in Healthy Subjects",Other,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 1,No,Yes,No,No,No,No,2018-03-12,204,Healthy Volunteers,FALSE,FALSE,2019-05-22,Phase 1,A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants,United States,Takeda
main,NCT03966170,https://clinicaltrials.gov/show/NCT03966170,Efficacy of Citicoline as Neuroprotector in Preterm; A Randomized Controlled Trial,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,No,CT.gov,Phase 3,Yes,No,No,No,No,No,2019-05-01,40,Pre-Term,FALSE,FALSE,2019-05-24,Phase 3,Citicoline as Neuroprotector in Preterm,Egypt,Sherief Abd-Elsalam
im,NCT03968640,https://clinicaltrials.gov/show/NCT03968640,Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,NA,NA,NA,NA,NA,NA,2019-08-01,290,Multiple Organ Failure,FALSE,FALSE,2019-05-28,Phase 3,Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients,NULL,American Burn Association
main,NCT03973177,https://clinicaltrials.gov/show/NCT03973177,"Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain Following Total Knee Arthroplasty: a Pilot Prospective, Randomized, Crossover Trial",Treatment,NA,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 4,No,Yes,No,No,No,No,2019-05-24,40,"Pain, Chronic",FALSE,FALSE,2019-05-28,Phase 4,Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain,United States,Northwestern University
main,NCT03985995,https://clinicaltrials.gov/show/NCT03985995,"Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults",Other,NA,"Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Undefined,No,No,No,No,Yes,No,2019-09-16,20,Pain Sensation;Hyperalgesia;Allodynia,FALSE,FALSE,2019-06-11,N/A,"Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults",Switzerland,"University Hospital, Basel, Switzerland"
main,NCT03991520,https://clinicaltrials.gov/show/NCT03991520,Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms,Treatment,NA,"Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 1,No,Yes,No,No,No,No,2020-04-01,20,Endometriosis;Anakinra;Markers of Inflammation,FALSE,TRUE,2019-05-27,Early Phase 1,Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms,United States,"University of California, San Diego"
main,NCT03998085,https://clinicaltrials.gov/show/NCT03998085,Study of Anlotinib Single Drug as the Maintenance Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC),Treatment,NA,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,No,CT.gov,Undefined,No,No,No,Yes,No,No,2019-03-05,40,Non-Small Cell Lung Cancer,FALSE,FALSE,2019-06-23,N/A,Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC,China,First Hospital of Jilin University
main,NCT04003688,https://clinicaltrials.gov/show/NCT04003688,Strategy to Calculate Magnesium Sulfate Dose in Obese Patients. A Randomized and Blind Trial.,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Undefined,No,No,Yes,No,No,No,2019-11-01,75,Magnesium Sulfate;Postoperative Pain;Obesity,FALSE,FALSE,2019-06-24,N/A,Magnesium Sulfate Dose in Obese Patients.,Brazil,University of Sao Paulo General Hospital
main,NCT04014556,https://clinicaltrials.gov/show/NCT04014556,Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema. One Year Results of a Randomized Clinical Trial,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Undefined,NA,NA,NA,NA,NA,NA,2016-04-01,40,Diabetic Macular Edema,FALSE,FALSE,2019-07-05,N/A,Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema,NULL,University of Alexandria
im,NCT04016246,https://clinicaltrials.gov/show/NCT04016246,Respiratory Effect of the LISA (Less Invasive Surfactant Administration) Method With Sedation by Propofol Versus Absence of Sedation: Double-blind Comparative Randomized Clinical Trial.,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,No,No,No,No,Yes,No,2019-10-07,542,Respiratory Distress Syndrome in Premature Infant,FALSE,FALSE,2019-06-07,Phase 3,Respiratory Effect of the LISA Method With Sedation by Propofol Versus Absence of Sedation.,France,"University Hospital, Grenoble"
main,NCT04019704,https://clinicaltrials.gov/show/NCT04019704,"AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,No,CT.gov,Phase 3,No,Yes,No,No,No,No,2019-06-20,327,Depression;Major Depressive Disorder,FALSE,FALSE,2019-07-11,Phase 3,A Trial of AXS-05 in Patients With Major Depressive Disorder,United States,"Axsome Therapeutics, Inc."
im,NCT04020003,https://clinicaltrials.gov/show/NCT04020003,A Clinical Study on Levosimendan Improvement of Prognosis of ARDS Patients by Optimizing Pulmonary Hemodynamics,Treatment,NA,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,No,CT.gov,Phase 3,No,No,No,Yes,No,No,2019-07-01,120,"ARDS, Human",FALSE,FALSE,2019-07-02,Phase 3,A Clinical Study on Levosimendan Improvement of Prognosis of ARDS Patients by Optimizing Pulmonary Hemodynamics,China,Shenzhen Second People's Hospital
im,NCT04020263,https://clinicaltrials.gov/show/NCT04020263,Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,No,No,No,No,Yes,No,2019-12-01,610,Cardiogenic Shock,FALSE,FALSE,2019-06-28,Phase 3,Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock,France,"Central Hospital, Nancy, France"
im,NCT04023305,https://clinicaltrials.gov/show/NCT04023305,Sevoflurane pharmacokInetics During Inhaled Sedation Relies on the Morphotype of ARDS in ICU Patients,Treatment,NA,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).,Yes,No,Yes,Yes,CT.gov,Undefined,No,No,No,No,Yes,No,2020-02-23,30,Acute Respiratory Distress Syndrome,FALSE,FALSE,2019-07-10,N/A,Sevoflurane PharmacokInetics in ARDS,France,"University Hospital, Clermont-Ferrand"
main,NCT04026438,https://clinicaltrials.gov/show/NCT04026438,Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT),Other,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 4,No,No,No,Yes,No,No,2018-12-12,140,"Complication, Postoperative;Regeneration Liver",FALSE,FALSE,2019-07-11,Phase 4,Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT),India,"Institute of Liver and Biliary Sciences, India"
main,NCT04049669,https://clinicaltrials.gov/show/NCT04049669,Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG,Treatment,NA,Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,No,No,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2019-10-02,140,Glioblastoma;Medulloblastoma;Ependymoma;Diffuse Intrinsic Pontine Glioma,FALSE,FALSE,2019-08-02,Phase 2,Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG,United States,Theodore S. Johnson
main,NCT04061590,https://clinicaltrials.gov/show/NCT04061590,A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer,Treatment,NA,Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).,NA,No,No,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2019-12-21,84,Lung Non-Small Cell Carcinoma;Stage I Lung Cancer AJCC v8;Stage IA1 Lung Cancer AJCC v8;Stage IA2 Lung Cancer AJCC v8;Stage IA3 Lung Cancer AJCC v8;Stage IB Lung Cancer AJCC v8;Stage II Lung Cancer AJCC v8;Stage IIA Lung Cancer AJCC v8;Stage IIB Lung Cancer AJCC v8;Stage IIIA Lung Cancer AJCC v8,FALSE,FALSE,2019-08-16,Phase 2,Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer,United States,"University of California, San Francisco"
main,NCT04061876,https://clinicaltrials.gov/show/NCT04061876,Ruxolitinib in Combination With Corticosteroid as First Line Therapy for the Treatment of High Risk Acute Graft-Versus-Host Disease,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 2,No,No,No,Yes,No,No,2019-06-01,198,aGVHD;Stem Cell Transplant Complications,FALSE,FALSE,2019-08-17,Phase 2,First Line Therapy for High Risk Acute GVHD,China,Chinese PLA General Hospital
main,NCT04063267,https://clinicaltrials.gov/show/NCT04063267,Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-10-27,240,Cigarette Smoking;Addiction;E Cig Use,FALSE,FALSE,2019-08-19,Phase 2,Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder,United States,NYU Langone Health
main,NCT04078386,https://clinicaltrials.gov/show/NCT04078386,"A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,No,CT.gov,Phase 2,No,No,No,Yes,No,No,2019-06-28,30,Primary Sjögren's Syndrome,FALSE,FALSE,2019-07-18,Phase 2,A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome,China,RemeGen
main,NCT04082325,https://clinicaltrials.gov/show/NCT04082325,"Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-oral-dose Study Investigating the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Properties of Lu AF88434 and Open-label Crossover Study to Investigate the Intra-individual Variability, Metabolic Profile, and Effect of Food on Lu AF88434 in Healthy Young Men",Treatment,NA,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Yes,Yes,Yes,No,CT.gov,Phase 1,No,No,No,No,Yes,No,2019-07-23,66,Healthy,FALSE,FALSE,2019-09-05,Phase 1,Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men,Netherlands,H. Lundbeck A/S
main,NCT04082910,https://clinicaltrials.gov/show/NCT04082910,Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells,Treatment,NA,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,No,No,Yes,CT.gov,Phase 2,No,No,No,Yes,No,No,2019-09-15,30,Solid Tumor;Hematologial Malignancy,FALSE,FALSE,2019-09-04,Phase 1/Phase 2,Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells,China,Chinese PLA General Hospital
im,NCT04094857,https://clinicaltrials.gov/show/NCT04094857,A Phase 1 First-In-Human Study of HBN-1 in Patients Resuscitated Following Out-of-Hospital Cardiac Arrest,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 1,No,Yes,No,No,No,No,2019-10-30,18,Cardiac Arrest,FALSE,FALSE,2019-09-17,Phase 1,Phase 1 Study of HBN-1,United States,"Hibernaid, Inc"
main,NCT04095936,https://clinicaltrials.gov/show/NCT04095936,A Phase 2/3 Study of AMG531 Combined With Ciclosporin A in Patients With Aplastic Anemia Previously Untreated With Immunosuppressive Therapy,Treatment,NA,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 3,No,No,No,Yes,No,No,2019-12-03,24,Aplastic Anemia,JPRN-JapicCTI-194962,FALSE,2019-09-18,Phase 2/Phase 3,Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia,Japan,"Kyowa Kirin Co., Ltd."
main,NCT04097080,https://clinicaltrials.gov/show/NCT04097080,"Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease",Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 1,No,No,No,No,Yes,No,2019-12-15,60,Parkinson Disease,FALSE,FALSE,2019-09-18,Phase 1,"Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease",Russian Federation,Nobilis Therapeutics Inc.
main,NCT04114747,https://clinicaltrials.gov/show/NCT04114747,"Impact of Continuous Renal Replacement Therapy on Renal Oxygenation, Blood Flow and Function",Prevention,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Undefined,No,No,No,No,Yes,No,2020-08-31,20,AKI;Continuous Renal Replacement Therapy;Dialysis;Intensive Care;Renal Blood Flow;Renal Failure;Blood Pressure,FALSE,FALSE,2019-09-23,N/A,Renal Physiology During Continuous Renal Replacement Therapy,Sweden,"Sahlgrenska University Hospital, Sweden"
im,NCT04130230,https://clinicaltrials.gov/show/NCT04130230,Safety and Efficacy of Neostigmine Infusion as Adjuvant Therapy in Sepsis and Septic Shock,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).,Yes,Yes,Yes,No,CT.gov,Phase 2,Yes,No,No,No,No,No,2019-03-06,50,"Sepsis, Septic Shock",FALSE,FALSE,2019-10-08,Phase 2,Adjuvant Use of Neostigmine in Sepsis and Septic Shock.,Egypt,Mansoura University
im,NCT04137887,https://clinicaltrials.gov/show/NCT04137887,Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine Versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older,Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,No,No,No,No,Yes,No,2019-11-04,121000,Influenza (Healthy Volunteers),EUCTR2019-001401-25-FI,FALSE,2019-10-11,Phase 3,Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older,Finland,"Sanofi Pasteur, a Sanofi Company"
main,NCT04144192,https://clinicaltrials.gov/show/NCT04144192,"Phase 1, Randomized, Comparative Pharmacokinetic Study of Bolus Intravenous Lidocaine 0.7 mg/kg, Lidocaine Patch 1.8%, and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects",Other,NA,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 1,NA,NA,NA,NA,NA,NA,2014-04-28,58,Healthy,FALSE,FALSE,2019-10-28,Phase 1,Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects,NULL,"Scilex Pharmaceuticals, Inc."
im,NCT04146623,https://clinicaltrials.gov/show/NCT04146623,"A Randomized Double-Blind, Placebo Controlled, Phase I Study of the Safety, Tolerability and Immunogenicity of a Live Attenuated H1N1 Vaccine in Healthy Individuals",Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Care Provider).",Yes,Yes,Yes,No,CT.gov,Phase 1,No,No,No,No,No,Yes,2019-05-07,33,Influenza,FALSE,FALSE,2019-10-28,Phase 1,"Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray",Australia,"Codagenix, Inc"
im,NCT04198883,https://clinicaltrials.gov/show/NCT04198883,SINGaporean Program Performed With an eXPANsion Medical Device,Treatment,NA,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,No,CT.gov,Phase 2,No,No,No,Yes,No,No,2018-11-27,10,Heart Attack,FALSE,FALSE,2019-07-04,Phase 1/Phase 2,SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand),Singapore,CellProthera
covid,NCT04282902,https://clinicaltrials.gov/show/NCT04282902,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 3,No,No,No,Yes,No,No,2020-02-04,294,Novel Coronavirus Pneumonia;Pneumonia;Pirfenidone,FALSE,FALSE,2020-02-10,Phase 3,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,China,Huilan Zhang
covid,NCT04293887,https://clinicaltrials.gov/show/NCT04293887,"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon a1ß in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan",Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 1,Unreported,Unreported,Unreported,Unreported,Unreported,Unreported,2020-03-01,328,COVID-19;Recombinant Human Interferon a1ß,FALSE,FALSE,2020-02-15,Early Phase 1,Efficacy and Safety of IFN-a2ß in the Treatment of Novel Coronavirus Patients,NA,Tongji Hospital
covid,NCT04325061,https://clinicaltrials.gov/show/NCT04325061,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 4,No,No,No,No,Yes,No,2020-04-03,200,Acute Respiratory Distress Syndrome Caused by COVID-19,FALSE,FALSE,2020-03-25,Phase 4,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Spain,Dr. Negrin University Hospital
covid,NCT04333472,https://clinicaltrials.gov/show/NCT04333472,"Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,No,No,Yes,No,No,2020-10-06,40,COVID-19;Coronavirus Infection,FALSE,FALSE,2020-04-01,Phase 2,Piclidenoson for Treatment of COVID-19,Israel,Can-Fite BioPharma
covid,NCT04334005,https://clinicaltrials.gov/show/NCT04334005,Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Undefined,No,No,No,No,Yes,No,2020-04-10,200,Patients Infected With COVID-19,FALSE,FALSE,2020-03-29,N/A,Vitamin D on Prevention and Treatment of COVID-19,Spain,Universidad de Granada
covid,NCT04334148,https://clinicaltrials.gov/show/NCT04334148,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial),Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,No,Yes,No,No,No,No,2020-04-22,1363,COVID-19,FALSE,FALSE,2020-04-02,Phase 3,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine,United States,Adrian Hernandez
covid,NCT04342728,https://clinicaltrials.gov/show/NCT04342728,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Other,NA,Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Undefined,No,Yes,No,No,No,No,2020-04-08,520,COVID;Corona Virus Infection,FALSE,FALSE,2020-04-08,N/A,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,United States,The Cleveland Clinic
covid,NCT04342897,https://clinicaltrials.gov/show/NCT04342897,"A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-04-20,95,COVID-19;Pneumonia,FALSE,FALSE,2020-04-10,Phase 2,A Study of LY3127804 in Participants With COVID-19,United States,Eli Lilly and Company
covid,NCT04343092,https://clinicaltrials.gov/show/NCT04343092,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),Treatment,NA,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 1,No,No,No,Yes,No,No,2020-04-18,16,COVID 19,FALSE,FALSE,2020-04-05,Phase 1,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Iraq,University of Baghdad
covid,NCT04345861,https://clinicaltrials.gov/show/NCT04345861,Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,No,No,No,No,Yes,No,2020-04-11,7,"Coronavirus Infection;Pneumonia, Viral",FALSE,FALSE,2020-04-05,Phase 2/Phase 3,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),France,"University Hospital, Montpellier"
covid,NCT04346329,https://clinicaltrials.gov/show/NCT04346329,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2,Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Care Provider).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,No,No,Yes,No,No,No,2020-04-20,86,COVID,FALSE,FALSE,2020-04-10,Phase 3,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19,Colombia,Universidad Nacional de Colombia
covid,NCT04347239,https://clinicaltrials.gov/show/NCT04347239,"A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-04-15,390,Coronavirus Disease 2019,TRUE,FALSE,2020-04-13,Phase 2,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),United States,"CytoDyn, Inc."
covid,NCT04350580,https://clinicaltrials.gov/show/NCT04350580,Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,No,No,No,No,Yes,No,2020-04-11,138,Acute Respiratory Distress Syndrome;COVID-19,FALSE,FALSE,2020-04-08,Phase 3,Polyvalent Immunoglobulin in COVID-19 Related ARds,France,Centre Hospitalier St Anne
covid,NCT04361214,https://clinicaltrials.gov/show/NCT04361214,Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19,Treatment,NA,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 1,No,Yes,No,No,No,No,2020-05-05,20,COVID-19,FALSE,FALSE,2020-04-22,Phase 1,Leflunomide in Mild COVID-19 Patients,United States,University of Chicago
covid,NCT04362189,https://clinicaltrials.gov/show/NCT04362189,"A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-06-30,100,COVID-19,FALSE,FALSE,2020-04-21,Phase 2,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,United States,Hope Biosciences
covid,NCT04365309,https://clinicaltrials.gov/show/NCT04365309,Protective Effect of Aspirin on COVID-19 Patients,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 3,No,No,No,Yes,No,No,2020-02-10,128,Novel Coronavirus Pneumonia;Aspirin;Treatment,FALSE,FALSE,2020-04-24,Phase 2/Phase 3,Protective Effect of Aspirin on COVID-19 Patients,China,Xijing Hospital
covid,NCT04366063,https://clinicaltrials.gov/show/NCT04366063,Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 3,No,No,No,Yes,No,No,2020-04-05,60,Covid-19,FALSE,FALSE,2020-04-20,Phase 2/Phase 3,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,"Iran, Islamic Republic of",Royan Institute
covid,NCT04366908,https://clinicaltrials.gov/show/NCT04366908,Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS),Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 2,Unreported,Unreported,Unreported,Unreported,Unreported,Unreported,2020-04-28,1008,SARS-CoV 2;COVID19;SARS (Severe Acute Respiratory Syndrome);Cytokine Release Syndrome;Cytokine Storm,FALSE,FALSE,2020-04-25,Phase 2,Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome,NA,Maimónides Biomedical Research Institute of Córdoba
covid,NCT04390178,https://clinicaltrials.gov/show/NCT04390178,Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease,Treatment,NA,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,No,Not applicable,No,Yes,CT.gov,Phase 2,No,No,No,No,Yes,No,2020-04-10,10,COVID-19,FALSE,FALSE,2020-04-10,Phase 1/Phase 2,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),Sweden,Joakim Dillner
covid,NCT04394377,https://clinicaltrials.gov/show/NCT04394377,Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).,Yes,Yes,Yes,Yes,CT.gov,Phase 4,No,No,Yes,No,No,No,2020-06-21,600,Coronavirus Infection,FALSE,FALSE,2020-05-08,Phase 4,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Brazil,Brazilian Clinical Research Institute
covid,NCT04412018,https://clinicaltrials.gov/show/NCT04412018,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19),Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-06-04,100,COVID-19;Inflammatory Response,FALSE,FALSE,2020-05-29,Phase 2,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,Canada,Canadian Medical and Surgical Knowledge Translation Research Group
covid,NCT04419623,https://clinicaltrials.gov/show/NCT04419623,"A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer",Treatment,NA,"Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",No,No,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-07-09,146,COVID-19;Sars-CoV2;Cancer;Solid Tumor;Carcinoma;Blood Cancer,TRUE,FALSE,2020-06-03,Phase 1/Phase 2,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,United States,"Telios Pharma, Inc."
covid,NCT04423861,https://clinicaltrials.gov/show/NCT04423861,"A Phase III, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Efficacy and Safety of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Non-critical Condition",Treatment,Yes,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,Unreported,Unreported,Unreported,Unreported,Unreported,Unreported,2020-12-01,380,covid19,FALSE,TRUE,2020-06-08,Phase 3,Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19,NA,Azidus Brasil
covid,NCT04436458,https://clinicaltrials.gov/show/NCT04436458,"Phase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and Symptoms",Treatment,Yes,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,Unreported,Unreported,Unreported,Unreported,Unreported,Unreported,2020-12-01,100,COVID,FALSE,TRUE,2020-06-16,Phase 2,Niclosamide In Moderate COVID-19,NA,"First Wave Bio, Inc."
covid,NCT04442048,https://clinicaltrials.gov/show/NCT04442048,"COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure",Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 3,No,Yes,No,No,No,No,2020-06-25,1500,Cancer;Covid-19,FALSE,FALSE,2020-06-19,Phase 3,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,Canada,Canadian Cancer Trials Group
covid,NCT04446377,https://clinicaltrials.gov/show/NCT04446377,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-07-15,142,COVID-19 Disease,FALSE,FALSE,2020-06-23,Phase 2,A Study of LAM-002A for the Prevention of Progression of COVID-19,United States,"AI Therapeutics, Inc."
covid,NCT04447235,https://clinicaltrials.gov/show/NCT04447235,"Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,No,Yes,No,No,No,2020-07-23,176,Cancer;COVID;Coronavirus Infection,FALSE,FALSE,2020-06-22,Phase 2,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,Brazil,Instituto do Cancer do Estado de São Paulo
covid,NCT04452669,https://clinicaltrials.gov/show/NCT04452669,"Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-08-15,20,COVID-19,FALSE,FALSE,2020-06-29,Phase 2,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,United States,Aerogen Pharma Limited
covid,NCT04454307,https://clinicaltrials.gov/show/NCT04454307,Safety and Efficacy of Tramadol Adjuvant Therapy to Standard Care for COVID-19 Egyptian Patients: A Randomized Double Blind Controlled Clinical Trial,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,Unreported,Unreported,Unreported,Unreported,Unreported,Unreported,2020-07-01,100,COVID-19,FALSE,TRUE,2020-06-29,Phase 1/Phase 2,Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients,NA,Tanta University
covid,NCT04455815,https://clinicaltrials.gov/show/NCT04455815,"A Randomised Phase II/III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion",Treatment,NA,Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 3,No,No,No,No,Yes,No,2020-09-25,389,COVID-19 Infection,FALSE,FALSE,2020-06-25,Phase 2/Phase 3,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home,United Kingdom,Cancer Research UK
covid,NCT04460651,https://clinicaltrials.gov/show/NCT04460651,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,No,No,Yes,No,No,No,2020-08-14,2000,COVID19,FALSE,FALSE,2020-07-02,Phase 3,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,Argentina,Estudios Clínicos Latino América
covid,NCT04466280,https://clinicaltrials.gov/show/NCT04466280,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19 Disease in Healthcare Providers at Baqiyatallah Hospital in Tehran",Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Undefined,No,No,No,Yes,No,No,2020-07-15,180,COVID-19,FALSE,FALSE,2020-07-09,N/A,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19","Iran, Islamic Republic of",Baqiyatallah Medical Sciences University
covid,NCT04466540,https://clinicaltrials.gov/show/NCT04466540,"Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,No,CT.gov,Phase 4,No,No,Yes,No,No,No,2020-05-12,1300,COVID-19,FALSE,FALSE,2020-07-03,Phase 4,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),Brazil,Hospital Alemão Oswaldo Cruz
covid,NCT04468009,https://clinicaltrials.gov/show/NCT04468009,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Treatment,NA,Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 2,No,No,Yes,No,No,No,2020-06-25,36,SARS-Associated Coronavirus;Covid19;SARS-CoV Infection,FALSE,FALSE,2020-07-09,Phase 2,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Argentina,Hospital de Infecciosas Francisco Javier Muniz
covid,NCT04470531,https://clinicaltrials.gov/show/NCT04470531,Role of Co-trimoxazole in Severe COVID-19 Patients,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 2,No,No,No,Yes,No,No,2020-07-12,94,Covid19;Severe COVID-19 Patients,FALSE,FALSE,2020-07-11,Phase 2,Role of Co-trimoxazole in Severe COVID-19 Patients,Bangladesh,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh"
covid,NCT04483830,https://clinicaltrials.gov/show/NCT04483830,Sulodexide in the Treatment of Early Stages of COVID-19,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).,Yes,Yes,Yes,No,CT.gov,Phase 3,No,No,Yes,No,No,No,2020-06-05,243,Covid19,FALSE,FALSE,2020-07-22,Phase 2/Phase 3,Suloexide in the Treatment of Early Stages of COVID-19,Mexico,Clinedem
covid,NCT04487886,https://clinicaltrials.gov/show/NCT04487886,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-08-01,80,COVID-19,FALSE,TRUE,2020-07-23,Phase 2,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),United States,Emory University
covid,NCT04491994,https://clinicaltrials.gov/show/NCT04491994,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 3,No,No,No,Yes,No,No,2020-04-10,540,Covid19;Progression,FALSE,FALSE,2020-07-28,Phase 3,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Pakistan,UNICEF
covid,NCT04494399,https://clinicaltrials.gov/show/NCT04494399,"An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection",Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 2,No,No,No,Yes,No,No,2020-07-29,96,Covid19,FALSE,FALSE,2020-07-28,Phase 2,IFN Beta-1b and Ribavirin for Covid-19,Hong Kong,The University of Hong Kong
covid,NCT04494724,https://clinicaltrials.gov/show/NCT04494724,A Phase 2 Trial to Evaluate the Safety and Tolerability of Clazakizumab® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 Infection,Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,No,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-07-13,60,COVID-19 Infection,FALSE,FALSE,2020-07-21,Phase 2,Clazakizumab vs. Placebo - COVID-19 Infection,United States,The Methodist Hospital System
covid,NCT04498936,https://clinicaltrials.gov/show/NCT04498936,"Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial",Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 4,Yes,No,No,No,No,No,2020-07-15,240,COVID,FALSE,FALSE,2020-04-14,Phase 4,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,Egypt,Assiut University
covid,NCT04527081,https://clinicaltrials.gov/show/NCT04527081,"A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults",Prevention,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Yes,Yes,No,Yes,CT.gov,Phase 2,No,No,No,Yes,No,No,2020-08-31,30,COVID-19,FALSE,FALSE,2020-08-24,Phase 1/Phase 2,Study of COVID-19 DNA Vaccine (AG0302-COVID19),Japan,"AnGes, Inc."
covid,NCT04535856,https://clinicaltrials.gov/show/NCT04535856,"Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 1,No,No,No,Yes,No,No,2020-10-26,9,Covid19;Corona Virus Infection;SAR,FALSE,FALSE,2020-08-28,Phase 1,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,Indonesia,Ina-Respond
covid,NCT04541979,https://clinicaltrials.gov/show/NCT04541979,"Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 - a Phase 2, Single-blinded, Randomized Study",Treatment,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).,Yes,Yes,Yes,No,CT.gov,Phase 2,No,No,No,No,Yes,No,2020-06-04,100,COVID-19,FALSE,FALSE,2020-06-05,Phase 2,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,Sweden,Region Skane
covid,NCT04549376,https://clinicaltrials.gov/show/NCT04549376,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: an Open Label Randomized Clinical Trial,Prevention,NA,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Yes,Yes,No,No,CT.gov,Phase 2,No,No,No,Yes,No,No,2020-07-01,200,COVID19,FALSE,FALSE,2020-09-11,Phase 2,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Bangladesh,"Pi Research Consultancy Center, Bangladesh"
covid,NCT04563702,https://clinicaltrials.gov/show/NCT04563702,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers",Prevention,NA,Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).,NA,No,No,Yes,CT.gov,Phase 1,No,Yes,No,No,No,No,2020-09-21,35,Covid19,FALSE,FALSE,2020-09-21,Phase 1,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,United States,Vaxart
covid,NCT04564716,https://clinicaltrials.gov/show/NCT04564716,"?linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-?oV-2 Infection Prophylactic Treatment in Republic of Belarus",Prevention,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).",Yes,Yes,Yes,Yes,CT.gov,Phase 3,No,No,No,No,Yes,No,2020-09-28,100,Covid19,FALSE,FALSE,2020-09-24,Phase 3,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus",Belarus,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"
covid,NCT04565249,https://clinicaltrials.gov/show/NCT04565249,"A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)",Treatment,NA,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Yes,Yes,Yes,Yes,CT.gov,Phase 2,No,Yes,No,No,No,No,2020-10-22,36,Acute Respiratory Distress Syndrome;SARS-CoV-2,FALSE,FALSE,2020-09-15,Phase 2,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19",United States,"Pliant Therapeutics, Inc."
covid,NL8547,https://trialregister.nl/trial/8547,"REDUCING HOSPITAL ADMISSION OF ELDERLY IN SARS-CoV-2 PANDEMIC VIA THE INDUCTION OF TRAINED IMMUNITY BY BACILLUS CALMETTE-GUÉRIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL",NA,NA,"
                        Randomized: No, 
                        Masking: Single, 
                        Control: Placebo, 
                        Group: undefined, 
                        Type: 2 or more arms, randomized
",Yes,Yes,Yes,No,NTR,Unreported,No,No,No,No,Yes,No,2020-04-16,1600,COVID-19,FALSE,FALSE,2020-04-22,NA,"REDUCING HOSPITAL ADMISSION OF ELDERLY IN SARS-CoV-2 PANDEMIC VIA THE INDUCTION OF TRAINED IMMUNITY BY BACILLUS CALMETTE-GUÉRIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL",The Netherlands,Radboudumc
main,PACTR201908793583382,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=8297,Tranexamic Acid versus Carbetocin for Reduction of Blood loss during Abdominal Myomectomy,NA,NA,"Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using a randomization table created by a computer software program,Sealed opaque envelopes",Yes,Yes,Yes,No,PACTR,Undefined,Yes,No,No,No,No,No,2016-05-01,132,<br>myomectomy surgery;myomectomy surgery,FALSE,FALSE,2019-08-03,Not Applicable,Carbetocin for the reduction of blood loss during myomectomy,Egypt,faculty pf medicine suez canal university
im,PER-016-17,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=016-17,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA",NA,Yes,"Subjects who meet the entry criteria will be randomly assigned in a 1:1 ratio to receive delafloxacin or moxifloxacin. Randomization will be stratified by PORT Class, medical history of chronic obstructive pulmonary disease (COPD)/asthma, and prior systemic antimicrobial use. Enrollment will be limited to no more than 25% Port Class II and no more than 25% of subjects with prior antibacterial use. <br>Subjects will be randomized to receive either IV delafloxacin 300 mg every 12 hours (BID), with an option to switch to oral delafloxacin 450 mg BID; or IV moxifloxacin 400 mg every 24 hours (QD), with an option to switch to oral moxifloxacin 400 mg QD for the remaining doses. Subjects randomized to receive IV moxifloxacin 400 mg QD will receive alternating IV placebo QD to preserve the double blind nature of the study, such that all randomized subjects will receive an IV infusion on a BID basis. <br>The investigator may elect to switch subjects from moxifloxacin/moxifloxacin placebo",Yes,Yes,Yes,Yes,PER,Phase 3,Yes,Yes,Yes,Yes,Yes,Yes,2017-09-04,25,"-J159 Bacterial pneumonia, unspecified <br>Bacterial pneumonia, unspecified;J159;Bacterial pneumonia, unspecified",FALSE,FALSE,2017-07-26,III,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA",Germany;Belarus;Bulgaria;Latovia;Slovenia;Spain;Georgia;Hungary;Modalvia;Poland;Romania;Russian Federation;Ukraine;Australia;New Zealand;Serbia;South Africa;Argentina;Brazil;Canada;Chile;Colombia;Dominican Republic;Mexico;Peru;United States,"Melinta Therapeutics, Inc.,"
covid,RBR-876qb5,http://www.ensaiosclinicos.gov.br/rg/RBR-876qb5/,Eculizumab for the treatment of Covid-19 severe cases - : Eculizumabe for COVID,Treatment,NA,"Clinical trial treatment, single-group, open label, single-arm",No,Not applicable,No,No,RBR,Phase 2,No,No,Yes,No,No,No,2020-05-27,10,"Coronavirus disease <br>Coronavirus infection, unspecified ;A00-B99;Coronavirus infection, unspecified",FALSE,FALSE,2020-06-08,1-2,Treatment of severe cases of Covid-19 with Eculizumab,Brazil,"Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo - Ribeirão Preto, SP, Brazil"
im,RBR-96cy3k,http://www.ensaiosclinicos.gov.br/rg/RBR-96cy3k/,Interference of Magnesium Sulfate in onset time and duration of Rocuronium in different doses,Treatment,NA,"Clinical trial of treatment, parallel, double-blind, randomized controlled, two branch, phase 4",Yes,Yes,Yes,No,RBR,Phase 4,No,No,Yes,No,No,No,2014-01-01,180,"Aspiration pneumonia,  neuromuscular nondepolarizing agents, intratracheal intubation <br>Pneumonia, Aspiration <br>Neuromuscular Nondepolarizing Agents <br>Intubation, Intratracheal;Pneumonia, Aspiration;Neuromuscular Nondepolarizing Agents;Intubation, Intratracheal",FALSE,FALSE,2016-09-09,4,Evaluation of onset time and duration of Rocuronium in differet doses when used with Magnesium Sulfate,Brazil,"Hospital Universitário Cassiano Antônio de Moraes - Vitória, ES, Brazil"
covid,RPCEC00000321,https://rpcec.sld.cu/en/trials/RPCEC00000321-En,Expanded clinical use of CIGB-258 in the treatment of serious or critically ill patients by COVID-19 (COVID-19),Treatment,NA,Allocation: N/A: single arm study. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment,No,Not applicable,No,No,RPCEC,Undefined,No,No,Yes,No,No,No,2020-04-27,0,COVID-19 respiratory distress <br>COVID-19;Respiration Disorders;COVID-19,FALSE,FALSE,2020-06-22,N/A,VIDA study,Cuba,"Center for Genetic Engineering and Biotechnology (CIGB), in Havana"
main,TCTR20190109001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4325,"A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levocetirizine 5 mg relative to XyzalÂ® 5 mg tablets in healthy Thai volunteers under fasting condition",Treatment,NA,Randomized controlled trial,Yes,Yes,No,Yes,TCTR,Phase 1,No,No,No,Yes,No,No,2019-03-01,24,Bioequivalence study <br>Bioequivalence Bioequivalence study;Bioequivalence Bioequivalence study,FALSE,FALSE,2019-01-08,Phase 1,"A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levocetirizine 5 mg relative to XyzalÂ® 5 mg tablets in healthy Thai volunteers under fasting condition",Thailand,"Bio-innova and Synchron.Co.,Ltd"
im,TCTR20190614001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4533,Effectiveness of Tongue Cleaning plus Chemical Mouthwash Agents  into the Number of  Oral Microorganism  on the  Aspiration Pneumonia in Bedridden Elderly Patients :   A Cross over study,NA,NA,Randomized controlled trial,Yes,Yes,NA,Yes,TCTR,Phase 1,No,No,No,Yes,No,No,2019-08-01,12,- Aspiration pneumonia because the number of microorganism on the dorsal tongue  of the bedridden patients who were the elderly totally independent in the community <br>- tongue cleaning- Chemical mouthwash agent- Bedridden patients- Older people;- tongue cleaning- Chemical mouthwash agent- Bedridden patients- Older people,FALSE,FALSE,2019-03-06,Phase 1,Effectiveness of Tongue Cleaning plus Chemical Mouthwash Agents  into the Number of  Oral Microorganism  on the  Aspiration Pneumonia in Bedridden Elderly Patients :   A Cross over study,Thailand,Naresuan University
main,TCTR20190614007,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4900,"Comparative sebum control efficacy of BGM complex (Bakuchiol, Ginkgo, and Mannitol) combined with adapalene 0.1%/benzoyl peroxide 2.5% gel and adapalene 0.1%/benzoyl peroxide 2.5% gel monotherapy in mild to moderate acne vulgaris patients",NA,NA,Randomized controlled trial,Yes,Yes,NA,Yes,TCTR,Phase 3,No,No,No,Yes,No,No,2019-07-01,18,dysseborrheaacne vulgaris,FALSE,FALSE,2019-06-14,Phase 2/Phase 3,"Comparative sebum control efficacy of BGM complex (Bakuchiol, Ginkgo, and Mannitol) combined with adapalene 0.1%/benzoyl peroxide 2.5% gel and adapalene 0.1%/benzoyl peroxide 2.5% gel monotherapy in mild to moderate acne vulgaris patients",Thailand,"Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital"
